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ABSTRACT 
 
Despite the availability of Hepatitis B virus (HBV) vaccination for over three decades, this 
infection remains a major public health problem. Whilst the WHO recommends giving a birth 
dose of the vaccine, in South Africa, routine infant HBV vaccination commences at six weeks of 
age. This schedule is based on data from the pre-HIV era which showed transmission occurred 
via the horizontal, rather than the vertical route. In the era of HIV however, maternal HIV co-
infection may release HBV from immune control, resulting in higher HBV loads and increasing 
the risk of vertical transmission. The aim of this study was to determine the prevalence and 
character of HBV infection in HIV-exposed infected and uninfected infants. 
 
Residual plasma samples from routine HIV nucleic acid testing of 1000 HIV-exposed infants 
aged between 0 and 18 months from the Western Cape were tested. Samples were tested for 
HBsAg by ELISA (Murex HBsAg Version 3) and confirmed by neutralisation. HBV DNA was 
quantified using an in-house real-time PCR assay. Infants with HBsAg positive samples were 
followed up and a blood sample was collected from mother and child. Those HBsAg positive 
samples were tested for HBeAg/antiHBe (Diasorin) and HBsAg negative samples were tested for 
antiHBs. HBV DNA was quantified. The surface gene was sequenced and the HBV genotype 
determined by phylogenetic analysis using HepSEQ (www.hepseq.org.uk). Whole genome 
sequencing was also performed. 
 
Of 1000 samples tested, four samples were positive for HBsAg and/or HBV DNA, indicating a 
prevalence of HBV transmission of 0.4%. At follow-up, two of three infected infants were 
positive for HBsAg, with HBV viral loads of greater than 10
8
 IU/ml. The third infant was found 
to have cleared his infection and the fourth child was lost to follow up. These infected infants 
had all received HBV vaccination. All four mothers were HBeAg positive. Sequencing analysis 
showed the HBV strains from the two infants and four mothers belonged to subgenotype A1. The 
two mother-child paired sequences were identical. 
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The data from this study shows that vertical transmission of HBV infection in HIV-exposed 
infants from the Western Cape is occurring, despite vaccination. Data from the Western Cape, 
showing an HBV prevalence of 3.4% in HIV-infected pregnant women, and those presented here 
suggest a vertical transmission rate of HBV of 12%. This is despite the widespread use of 
tenofovir and lamivudine in HIV-infected women with low CD4 counts. This study provides data 
supporting calls to bring HBV vaccination closer to the time of birth. Further work is urgently 
needed to confirm these findings and to determine the rates of transmission in HIV-unexposed 
infants. 
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OPSOMMING 
Ten spyte van die beskikbaarheid van die Hepatitis B virus (HBV) inenting vir meer as drie 
dekades, hierdie infeksie bly 'n groot openbare gesondheid probleem. Terwyl die WGO aan 
beveel dat'n geboorte dosis van die entstof, in Suid-Afrika, roetine baba HBV inenting op die 
ouderdom van ses weke gegee word. Hierdie skedule is gebaseer op data van die pre-MIV era 
wat getoon het dat die oordrag plaasgevind het via die horisontale, eerder as die vertikale roete. 
In die era van MIV egter, moeder MIV ko-infeksie kan HBV vrylaat van immuun beheer, wat lei 
in hoër HBV vlakke en die verhoging van die risiko van vertikale oordrag. Die doel van hierdie 
studie was om die voorkoms en karakter van die HBV infeksie in MIV-besmette en onbesmette 
babas te bepaal. 
 
Residuele plasma monsters van roetine-MIV-nukleïensuur toetse van 'n 1000 MIV-blootgestelde 
babas tussen die ouderdomme van 0 en 18 maande van die Wes-Kaap was getoets. Monsters was 
getoets vir HBsAg deur ELISA (Murex HBsAg Version 3) en bevestig deur neutralisering. HBV 
DNA is gekwantifiseer deur gebruik te maak van 'n in-huis real-time PCR assay. Babas met 
HBsAg positiewe monsters was opgevolg en 'n bloedmonster is versamel van moeder en kind. 
Die HBsAg positiewe monsters was getoets vir HBeAg/antiHBe (Diasorin) en HBsAg negatiewe 
monsters was getoets vir antiHBs. HBV DNA was gekwantifiseer. Die oppervlak gene volgorde 
en genotipes was bepaal deur filogenetiese analise met behulp van HepSEQ 
(www.hepseq.org.uk). Die hele genoom-volgordebepaling was ook uitgevoer. 
 
Van die 1000 monsters wat getoets was, was vier monsters positief vir HBsAg en of HBV DNA, 
dit dui op 'n voorkoms van HBV oordrag van 0.4%. By op volg, twee van die drie besmette 
babas was positief vir HBsAg, met HBV virale vlakke van groter as 10
8
 IE/ml. Die derde baba 
was gevind dat sy infeksie opgeklaar het en die vierde kind was verlore as gevolg van op volg. 
Hierdie besmette babas het almal HBV inenting ontvang. Al vier moeders was HBeAg positief. 
Volgordebepaling analise het getoon die HBV stamme van die twee babas en vier moeders 
behoort aan subgenotype A1. Die twee moeder-kind gepaarde rye was homoloë. 
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Die data van hierdie studie toon dat die vertikale oordrag van HBV infeksie in MIV-
blootgestelde babas van die Wes-Kaap vind plaas, ten spyte van inenting. Data van die Wes-
Kaap, wat 'n HBV voorkoms van 3.4% in MIV-besmette swanger vroue, en dié wat hier 
aangebied is dui op 'n vertikale oordrag koers van 12% van die HBV. Dit is ten spyte van die 
wydverspreide gebruik van tenofovir en lamivudine in MIV-geïnfekteerde vroue met 'n lae CD4-
telling. Hierdie studie bied data wat ondersteunende oproepe van HBV inenting nader aan die tyd 
van die geboorte bring. Verdere werk is dringend nodig om die bevindinge te bevestig en die 
pryse van die oordrag in MIV-blootgestelde babas te bepaal. 
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CHAPTER ONE: INTRODUCTION 
 
Throughout the world, more than 350 million people are chronically infected with hepatitis B 
virus (HBV) (Lavanchy 2004). This is despite the availability of a safe and effective vaccine for 
more than three decades. Africa and Asia carry the burden of this infection with up to 58 million 
and 130 million chronic carriers respectively (Custer et al. 2004). HBV is endemic to subSaharan 
Africa (Custer et al. 2004), but the rate of HBV infection varies between 5% and 19% between 
different African countries (Custer et al. 2004) and even within African countries (Kew 1996). 
 
South Africa introduced HBV vaccination in 1995 to the local Expanded Programme on 
Immunization (EPI). The vaccine is first administered to infants at the age of six weeks, although 
the World Health Organization (WHO) recommends giving the first dose of the vaccine within 
24 hours of birth. The South African schedule was based on epidemiological data available at the 
time showing horizontal transmission was the most important route of transmission. Guidozzi et 
al. (1993) showed that only 1.21% of pregnant women were positive for hepatitis B surface 
antigen (HBsAg) and only 4.6% of these women were positive for hepatitis B e antigen 
(HBeAg). Thus very few women were at risk of transmitting vertically. Vos et al. (1980) found 
the prevalence of HBsAg in children between the ages of two and four to be 10%. A study in 
1983 by Prozesky et al. showed that the prevalence of HBsAg was only 1% in 103 unvaccinated 
infants aged less than six months compared to 6% in 256 older children between 0.5 and 5 years. 
The same prevalence was seen in Namibian infants younger than six months while 12.7% of 
children between the ages of one and six years were found to be HBsAg positive (Botha et al. 
1984). Abdool Karim et al. (1988) found none of 51 infants less than one year old to be positive 
for HBsAg, but showed that 1.7% of 343 children between the ages of one and four were HBsAg 
positive. In a study from the Gambia, no infant below the age of six months was found to be 
infected with HBV, but infants between the ages of two and four from one village had a 
prevalence of HBsAg of 17.6% (Whittle et al. 1983). These studies showed that African mothers 
had a low risk of transmitting the virus to their children perinatally and that children were being 
infected after the age of one year, indicating that the major mode of HBV transmission was 
horizontal. 
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However, these studies were carried out when the human immunodeficiency virus (HIV) 
epidemic was not yet established in South Africa. HIV is known to impact the outcome of 
infection with HBV. In immunosuppressed patients, viral replication is poorly controlled by the 
host immune system resulting in high viral loads (Colin et al. 1999) and lower rates of HBeAg 
clearance (Thio 2009), which increase the risks of mother-to-child (MTCT) transmission of HBV 
(Burk et al. 1994). Recent research has shown a varying prevalence of HBsAg from 0.4% to 23% 
(Barth et al. 2010; Barth et al. 2011; Boyles and Cohen, 2011; Lukhwareni et al. 2009) and a 
high prevalence of so-called occult hepatitis B infections (OBI), which are characterised by the 
presence of HBV DNA in the absence of HBsAg, in HIV-infected adults in South Africa (Barth 
et al. 2011; Firnhaber et al. 2009; Lukhwareni et al. 2009). In contrast, fewer studies have been 
carried out in the South African paediatric population in the HIV-era (Hino et al. 2001; Tsebe et 
al. 2001; Simani et al. 2009) and none have looked at vertical transmission of HBV. 
 
Currently, HIV-infected patients are not routinely screened for HBV infection, unless they fail 
first line antiretroviral therapy (ART) (National Department of Health, South Africa and South 
African National AIDS Council 2010a). HIV-infected adults are only started on ART, which 
may include two antiretroviral agents, tenofovir and lamivudine, that also have anti-HBV 
activity, if their CD4 counts are below 350 cells/mm
3
 (National Department of Health, South 
Africa and South African National AIDS Council, 2010b). However, renal impairment is a 
contraindication to tenofovir therapy and HBV-HIV co-infected patients may be on lamivudine 
monotherapy (National Department of Health, South Africa and South African National AIDS 
Council 2010b). With the roll-out of perinatal ART in South Africa, the majority of infants born 
to HIV-infected mothers are HIV-exposed but uninfected (Jones et al. 2011). These infants are 
born with immune deficiencies (Filteau 2009) and have less transfer of maternal antibodies 
(Filteau 2009; Jones et al. 2011) potentially making them more susceptible to infections with 
more severe outcomes than HIV-unexposed infants (Filteau 2009). HIV-infected infants are not 
routinely tested for HBsAg and are started on ART, including lamivudine as the only antiHBV 
agent, as soon as they are diagnosed with HIV (National Department of Health, South Africa and 
South African National AIDS Council 2010b). 
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The use of lamivudine in monotherapy leads to the emergence of drug-resistant mutants within 
the first year of use through mutations in the polymerase (pol) gene of the HBV genome 
(Honkoop 1997). These may alter the overlapping surface gene (Torresi 2002) resulting in the 
expression of a mutated immunogenic epitope on the surface protein (HBsAg) (Clements et al. 
2010). The wild-type HBsAg is usually used in HB vaccines and the mutated epitope may lead to 
the emergence of potential vaccine-escape mutants not neutralized by immunization-induced 
antibody (Clements et al. 2010). There is little data on the viral strains circulating in South Africa 
and whether any immune escape variants associated with drug resistance are being transmitted in 
the general population. 
 
To date, no post-vaccine studies have looked at vertical transmission of HBV or characterised 
the HBV strains in the HIV-exposed paediatric population. Furthermore, there is limited data on 
the epidemiology of HBV in the Western Cape. Extrapolation of the data from other South 
African provinces to the Western Cape is difficult since there are regional differences in the 
prevalence of HIV (Sherman and Lilian 2011) and HBV infections (Kew 1996). 
 
This study primarily sought to look at the prevalence of HBV infection in HIV-exposed infants 
and to investigate whether vertical transmission of HBV is occurring in South Africa in the 
context of the HIV epidemic. 
 
The aims of the study were: 
  
1. To determine the prevalence of active HBV infection in a sample population of HIV-
exposed infants  
2. To follow-up infected infants to determine the prevalence of persistent HBV infection 
3. To trace mothers of infected infants to investigate whether the transmission was vertical 
4. To characterise HBV and HBV infection in infected patients (infants and mothers) by 
determining viral load, HBeAg status, the HBV genotype and any drug-resistant/vaccine-
escape mutations in the pol/surface gene. 
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 STRUCTURE OF HBV 
 
Hepatitis B is the smallest known DNA virus with a genome of only 3.2 kilobases. The mature 
virion is known as a Dane particle and is 42nm in diameter (Dane et al. 1970). Its genome is 
enclosed in a nucleocapsid made of core protein dimers, which is itself surrounded by an 
envelope composed of surface proteins (Harrison, Dusheiko and Zuckerman 2009). 
The virus is unusual in several ways. Firstly, it is the only known partially-double stranded virus, 
with a complete minus and an incomplete plus strand (Delius et al. 1983). Secondly, unlike other 
DNA viruses, it uses the enzyme reverse transcriptase for its replication (Seeger et al. 1986). 
Thirdly, since its genome is so small, it has four open reading frames (ORFs) which all overlap 
each other in varying degrees (Nassal and Schaller 1993) as illustrated in Figure 2.1. These four 
ORFs code for structural proteins, secreted antigens and other proteins necessary for the virus’s 
replication in the host cell (Nassal and Schaller 1993; Seeger and Mason 2000). 
 
Polymerase ORF 
 
The polymerase ORF which is the longest ORF of the virus has four domains (Locarnini et al. 
2003): 
1. a primase domain which codes for a primase which primes the genome for replication 
and is covalently attached to the 5’ end of the minus strand in the mature virion,  
2. a spacer which does not seem to have any function,  
3. a polymerase domain, further divided into seven conserved subdomains named A to G 
(Bartholomeusz et al. 2004), which codes for a reverse transcriptase which is the largest 
and most important protein as it is responsible for replication of the virus and reverse 
transcription of the pregenomic ribonucleic acid (RNA) into DNA in the mature virion 
and  
4. a ribonuclease-H (RNase-H) domain which codes for RNAse which removes the RNA 
strand from the DNA-RNA hybrid formed by reverse transcription of the pregenomic 
RNA. It is also thought to play a role in viral RNA packaging, in optimizing priming of 
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the minus-strand DNA synthesis and in elongation of the minus-strand viral DNA (Chen, 
Robinson and Marion 1994; Locarnini et al. 2003). 
 
Within the polymerase subdomain C, is a tyrosine-methionine-aspartate-aspartate amino acid 
motif (the so-called YMDD motif) which is essential for reverse transcriptase activity and in 
which drug-resistance mutations to lamivudine may arise (Honkoop et al. 1997). 
 
Surface ORF 
 
The surface ORF is divided into three domains:  
1. the S domain codes for 226 amino acids which make up the small hepatitis B surface 
protein (SHBs) which is also known as the surface antigen. The smallest antigen is also 
the most prolifically secreted antigen produced by the virus, but is non-infectious in 
nature. The marketed recombinant vaccines against HBV commonly mimic the ‘a’ 
determinant, an immunogenic determinant which is present within the SHBs of all 
genotypes (Clements et al. 2010). Drug-resistance mutations in the polymerase domain 
affect this region as a result of overlap between the polymerase and surface ORFs and 
may result in vaccine-escape mutants (Carman et al. 1990; Clements et al. 2010) and 
escape detection by some surface antigen assays (Weber 2006). 
2. the PreS2 domain codes for 55 amino acids. The PreS2 and the S domain together code 
for the middle surface antigen (MHBs). Although it is known that MHBs can bind 
polymerized human serum albumin (Pontisso et al. 1989), its role still needs to be 
elucidated. 
3. the PreS1 region codes for 108 or 119 amino acids depending on the genotype. The 
PreS1, PreS2 and the S domains collectively code for the large surface antigen protein 
(LHBs) (Locarnini et al. 2003). This protein has been implicated in the attachment of the 
virus to the host receptor although the receptor itself has not yet been identified (Gripon 
et al. 1995; Pontisso et al. 1989). 
  
Stellenbosch University http://scholar.sun.ac.za
 23 
 
The three proteins produced by the surface ORF differ in size and are all found on the envelope 
of the virus in varying amounts; the most common is SHBs followed by MHBs and LHBs is the 
least present on the envelope of the virus (Locarnini et al. 2003). 
 
 
Figure 2. 1 HBV Genome showing overlapping ORFs and the potential for drug-resistance 
mutations in the pol region to influence the surface antigen protein (Source: Clements et al. 
(2010) Reproduced with permission) 
GFABCDE:conserved regions in polymerase domain; DR1, direct repeat sequence 1; DR2, direct repeat sequence 2; EcoR1, the 
cut site of the restriction endonuclease EcoR1 derived from E. coli; X, X gene encoding the HBV X protein; PreS1 and PreS2, 
large envelope proteins; S, the small envelope protein. 
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Core ORF 
 
The core ORF codes for two proteins, the core protein and the ‘e’ protein. The core protein is a 
structural protein making up the nucleocapsid of the virus (Harrison, Dusheiko and Zuckerman 
2009) and is also involved in viral replication whereas the ‘e’ protein is a secreted antigen with 
immunoregulatory properties (Chen et al. 2005) which has been implicated as a potential 
tolerogen (Milich et al. 1990). The two proteins have distinct functions and are recognized as 
being different entities by antibodies but cross-react at the T-cell level (Chen et al. 2005; Milich 
et al. 1990). 
 
The hepatitis B e antigen (HBeAg) is associated with high levels of replication of the virus and 
by extension, is a marker of infectiousness. However, ‘pre-core’ mutant strains of HBV have 
been identified in which a stop codon mutation in the pre-core region of the genome prevents the 
expression of the HBeAg (Hadziyannis and Vassilopoulos 2001). The viral loads in patients 
infected with these pre-core mutants can nonetheless be very high and they are infectious despite 
the absence of HBeAg (Fattovich 2003). Patients infected with precore mutants have been found 
to be at higher risk of fulminant infection and of developing more severe disease during chronic 
infections (Omata et al. 1991). 
 
X ORF 
 
The X ORF codes for the smallest product encoded by the virus, the hepatitis B x (HBx) protein 
which is only composed of 154 amino acids. HBx protein is known to be a transactivator of viral 
replication and has been shown to be essential for continued replication of the virus in vitro 
(Lucifora et al. 2011). HBx has been shown to be oncogenic in vitro although the exact 
mechanisms involving HBx and HBV-induced hepatocellular carcinoma (HCC) development are 
unclear (Kew 2011). Among those proposed are, the ability of HBx to inactivate the tumor-
suppressor p53, its anti- and pro-apoptotic effects and its ability to induce hypo-and hyper-
methylation of DNA (Kew 2011). 
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2.2 LIFE CYCLE AND REPLICATION 
 
Hepatitis B virus infects and replicates in human hepatocytes (Seeger and Mason 2000) although 
the viral DNA has been isolated in other cells of the body (Bouffard et al. 1990) including the 
human ovary (Yu et al. 2012). The entry mechanism and the receptor it binds to are currently 
unknown although the LHBs protein is thought to be the most likely candidate for binding to the 
host cell surface (Nassal and Schaller 1993; Locarnini et al. 2003). The steps following binding 
of the virus including penetration and uncoating of the virus are also not well-described (Seeger 
and Mason 2000), but lead to release of the nucleocapsid into the cell cytoplasm (Locarnini et al. 
2003). 
 
The core enclosing the viral DNA migrates to the nucleus where the genome becomes 
completely double-stranded and the ends are ligated to form a covalently closed circular (ccc) 
genome (Locarnini et al. 2003). The cccDNA is associated with histone and non-histone proteins 
to form the minichromosome (Bock et al. 2001) which is then transcribed to produce genomic 
and subgenomic messenger RNAs (mRNAs) (Seeger and Mason 2000). The subgenomic 
transcript of 2.4 kilobases (kb) is translated in the rough endoplasmic reticulum to the LHBs 
protein, the 2.1kb subgenomic transcript is translated to the MHBs and SHBs proteins and the 
0.7kb subgenomic mRNA is translated to the HBx protein (Locarnini et al. 2003). 
 
The genomic transcripts are 3.5kb in size and include the precore mRNA which is translated to 
the HBeAg and a smaller bicistronic pregenomic mRNA which codes for the core and 
polymerase proteins and is reverse transcribed by the polymerase within the core to form the 
incomplete genome (Locarnini et al. 2003). 
 
Nucleocapsids containing reverse transcribed RNA are selectively enveloped with the surface 
proteins in the Golgi apparatus and the viral particles are secreted from the cell through the 
secretory pathway (Seeger and Mason 2000). The virus is not cytopathic, that is, replication, 
production and release of mature virions do not result in lysis of the host cell (Harrison, 
Dusheiko and Zuckerman 2009). 
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One distinctive characteristic of HBV infection is chronicity. This persistence is maintained by 
the recycling of some core particles via the intracellular conversion pathway (Locarnini et al. 
2003). Some nucleocapsids are not secreted and are instead used to increase the numbers of 
cccDNA in the nucleus of the hepatocyte thus maintaining a constant pool of cccDNA in the cell 
without the need for multiple rounds of re-infection (Locarnini et al. 2003). The life cycle of 
HBV is summarised in Figure 2.2. 
 
 
 
Figure 2. 2 HBV life cycle HBV infection, replication, encapsidation and release from 
hepatocytes (Source: Feld and Locarnini (2002) Reproduced with permission.) 
ER: endoplasmic reticulum; ccc: covalently closed circular; pg: pregenomic; S: small; M: medium; L: large  
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2.3 EPIDEMIOLOGY OF HBV WITH EMPHASIS ON SOUTH AFRICA 
 
An estimated two billion people have been infected with the hepatitis B virus worldwide and 
approximately 378 million have chronic liver infections (Franco et al. 2012). Between 500 000 
and 1.2 million people die every year due to the acute or chronic consequences of hepatitis B 
(Lavanchy 2004). 
 
Africa and Asia have the highest prevalence of HBV. Africa itself carries 18% of the burden of 
disease associated with HBV infections (Kramvis and Kew 2007). In South Africa alone, it is 
estimated that three to four million black people are chronically infected (Kew 2008). The 
prevalence of HBsAg across the African continent is illustrated in Figure 2.3. 
 
Figure 2. 3 Prevalence of HBsAg across the African continent The prevalence in the non-
shaded countries is not known. (Source: Kramvis and Kew (2007) Reproduced with permission). 
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In South Africa, epidemiological studies have shown the prevalence of HBV infection to vary 
according to the region and the population under study. Song et al. (1988) reported a prevalence 
of HBsAg of 6.1% in South African Chinese women of child-bearing age. In contrast, a study by 
Kew et al. (1975) showed the prevalence of HBsAg in white mothers to be 0.16% whereas a later 
study by Kew et al. (1987) showed a prevalence of HBsAg of 1.31% in black women. 
 
The Kew study from 1987 also revealed a higher prevalence of HBV infection in rural-born 
women (4.0%) compared to the urban-born women (1.3%). A similar trend was observed in 
children in a study by Abdool Karim et al. (1988) where 6.3% of children from an urban area 
were found to be HBsAg positive compared to 18.5% of children from a rural area. The same 
study also found the prevalence of HBsAg to be much higher in institutionalized children 
(35.4%). 
 
Studies which were conducted in South Africa before the introduction of universal HBV 
vaccination provide a baseline against which the current prevalence of HBV can be compared. A 
study in 1983 by Prozesky et al. showed that the prevalence of HBsAg was only 1.0% in 103 
infants aged less than six months. Abdool Karim et al. (1988) found the prevalence of HBsAg to 
be 1.5% in unvaccinated urban infants aged less than two years but none of the infected infants 
were less than one year old. A larger study conducted at the time of HB vaccine introduction to 
South Africa between 1995 and 1996 by Vardas et al. (1999) found a much higher prevalence of 
HBsAg of 9% in unvaccinated infants aged less than two years. The large discrepancy observed 
between these studies can be attributed to the small sample size investigated for that age group in 
the Prozesky and Abdool Karim studies and possible regional differences in the prevalence of 
HBV as has been been described previously (Kew et al. 1996). Studies after the introduction of 
the HB vaccine have shown a decrease in the prevalence of HBsAg in the vaccinated population. 
Hino et al. (2001) compared the rate of HBV infection between vaccinated children and 
unvaccinated children and found a decrease in the prevalence of HBV DNA from 6.5% in the 
unvaccinated cohort to 0.3% in the vaccinated group. Simani et al. (2009) reported 3/303 of their 
cohort of vaccinated children to be positive for HBsAg. A study by Tsebe et al. (2001) found 
none of the tested children to be positive for HBsAg. 
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However, these studies were carried out before the HIV epidemic was established in South 
Africa when horizontal transmission of HBV was thought to predominate. In the HIV-era, the 
viral loads in co-infected mothers may be higher as a consequence of loss of immune control 
(Thio 2009) potentially making vertical transmission a bigger problem than previously thought. 
 
 
2.4 DISTRIBUTION OF GENOTYPES AND THEIR CLINICAL SIGNIFICANCE 
 
Currently, there are eight major genotypes of HBV, named A to H, which are in circulation 
worldwide. Genomic differences of at least 8% are required for sequences to qualify as a new 
genotype (Kramvis et al. 2005). Following this criteria, two additional genotypes, I and J, have 
recently been described but they are not as well characterised (Huy et al. 2008; Tatematsu et al. 
2009) and the classification of genotype I is controversial (Kurbanov et al. 2008). Within some 
of the genotypes, HBV strains which differ by at least 4% but less than 8% are classified into 
subgenotypes. These genotypes and their subgenotypes are distributed in specific regions of the 
world (Figure 2.4) (Kramvis et al. 2005). 
 
Within Africa, HBV strains belonging to genotypes A, D and E predominate. Genotype A is 
most prevalent in Southern and East Africa and subgenotype A1 has been commonly isolated in 
African patients including South Africa (Kramvis and Kew 2007). Other less common 
subgenotypes, A3 to A7, have been described in West and Central African countries (Kramvis 
and Kew 2007; Hübschen et al. 2010; Pourkarim et al. 2010a) although it is suggested that 
subgenotypes A3, A 4 and A5 might have been misclassified (Pourkarim et al. 2010b). 
Subgenotype A2 on the other hand is most commonly seen in Europe and Japan (Kramvis et al. 
2005; Tamada et al. 2012). Genotype A does not produce pre-core mutants as typically seen with 
genotype D with a stop codon at position 1896 of the precore region (Kramvis 2008). This is 
because of the instability this mutation would cause in the folding of the pregenomic mRNA 
during encapsidation (Kramvis 2008). However, mutants with a stop codon at position 1862 of 
the precore region have been identified and have been hypothesised to reduce the expression of 
HBeAg (Kramvis 2008). 
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Genotype D is mostly concentrated in the Mediterranean region (Kramvis et al. 2005) and is 
therefore the most common genotype in North Africa. Isolates belonging to genotype D have 
been described in South Africa. However, the strains found in these two different geographical 
areas belong to different subgenotypes (Kramvis and Kew 2007). 
 
Genotype E which is an African genotype is most commonly seen in Central and West Africa 
(Kramvis and Kew 2007). 
 
 
Figure 2. 4 Phylogenetic tree representing the worldwide distribution of HBV genotypes 
(Source: Kramvis et al. (2005) Reproduced with permission.) 
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 These different genotypes have an impact on treatment as they show different disease 
progression have different susceptibilities to therapy. These are summarised in Table 2.1. 
 
Table 2. 1 Comparison of clinical and virological differences among hepatitis B virus 
genotypes. (Adapted from Lin and Kao (2011) Reproduced with permission.) 
GENOTYPE A D E 
Clinical characteristics    
Modes of transmission Horizontal horizontal horizontal 
Tendency of chronicity Higher Lower ND 
Positivity of HBeAg Higher Lower  ND 
HBeAg seroconversion Earlier Later ND 
HBsAg seroclearance More Less ND 
Histologic activity Lower Higher ND 
Clinical outcome (cirrhosis and HCC) Worse Worse ND 
Response to interferon alpha Higher Lower ND 
Response to nucleos(t)ide analogues  ND ND 
Virologic characteristics    
Serum HBV DNA level ND ND ND 
Frequency of precore A 1896 mutation Lower Higher ND 
Frequency of basal core promoter 
T1762/A1764 mutation 
Higher Lower ND 
Frequency of pre-S deletion mutation ND ND ND 
ND: No available data 
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2.5 NATURAL HISTORY OF HBV INFECTION 
 
Acute infection 
 
HBV infection can lead to a self-limiting acute disease primarily affecting the liver which will 
clear within six months of infection. HBV has an incubation period of 90 to 150 days following 
which, markers of infection such as HBsAg and HBV DNA become detectable using the 
currently available commercial assays. Patients will normally have an elevated alanine 
aminotransferase (ALT) level. ALT is a liver enzyme released in the bloodstream during an 
episode of inflammation in the liver. The serological profile of acute, resolving hepatitis B 
infection is shown in Figure 2.5. Patients with an acute infection will show varied symptoms, 
ranging from nausea and vomiting to rashes and will often progress to jaundice (Previsani and 
Lavanchy 2002). About 1% of acute cases develop into fulminant hepatitis which is often fatal in 
adults (Previsani and Lavanchy 2002). There is no specified treatment for acute HBV infection 
unless patients are suffering from fulminant hepatitis B or protracted severe acute hepatitis B 
(Lok and McMahon 2009). In 95% of adults and only 10% of newborns, HBsAg will clear 
within three months with the development of protective antiHBs antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 5 Serological profile of acute, resolving hepatitis B infection (Source Harrison, 
Dusheiko and Zuckerman (2009) Reproduced with permission). HBeAg: hepatitis B e antigen; HBsAg: 
hepatitis B surface antigen; Anti-HBc: antibody to hepatitis B core antigen; Anti-HBs: antibody to hepatitis B surface antigen; 
Anti-HBe: antibody to hepatitis B e antigen. 
Stellenbosch University http://scholar.sun.ac.za
 33 
 
Chronic infection 
 
The most severe consequences of HBV infection are seen in chronically-infected patients who 
may develop cirrhosis and HCC decades after the initial infection. Chronic HBV infection is 
defined as HBsAg positivity for more than six months.  
 
Age at infection is an important risk factor for development of chronicity. Vertical transmission 
from HBeAg-positive mothers has a 90% risk of resulting in a chronic infection (Beasley et al. 
1977). This has been attributed to the immaturity of the infants’ immune systems (Hadziyannis 
2011). Horizontal transmission before the age of five years has a reduced risk of chronicity of 
10-30% (Beasley et al. 1982) and in adults, the risk of chronicity is less than 5% (Lok and 
McMahon 2009). 
 
Chronic HBV infection is progressive and can be divided into four phases (illustrated in Figure 
2.5) although not every patient will experience all stages in a particular order (Dandri and 
Locarnini 2012). 
 
Immune tolerant phase 
 
The first is the immune tolerant phase, which occurs mostly in infants who are infected vertically 
and in whom it may last for decades (Fattovich et al. 2008). Older children and adults may 
experience the immune tolerant phase transiently (Fattovich et al. 2008; Yim and Lok, 2006). 
During this stage, the virus is not cleared by the immune system of the patients. As a result, the 
patient has high viral loads (>20 000 IU/ml), high levels of HBeAg and HBsAg (Dandri and 
Locarnini 2012), but normal or mildly elevated levels of liver enzymes (ALT and aspartate 
aminotransferase) with minimal liver damage (Fattovich et al. 2008). 
 
Immune clearance/HBeAg-positive chronic hepatitis B 
 
During the immune clearance phase, immune tolerance to HBV is lost and the virus is cleared by 
the immune system (Fattovich et al. 2008; Yim and Lok 2006). Typically in this phase, 
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inflammation of the liver, elevated ALT levels and fluctuating HBV DNA levels (>20 000 
IU/ml) are observed (Dandri and Locarnini 2012; Fattovich et al. 2008).  
 
Eventually, in most patients, this stage will result in the clearance of HBeAg and the appearance 
of antibody to hepatitis B e antigen (antiHBe) marking the transition to the next phase (Fattovich 
et al. 2008). Some patients however, will periodically show fluctuating levels of DNA replication 
and flares in liver enzyme levels (Yim and Lok 2006). The duration of this phase and the severity 
of the liver enzyme flares have been described as risk factors for cirrhosis and HCC (Dandri and 
Locarnini 2012; Yim and Lok 2006).  
 
Immune control phase 
 
The following phase is the inactive HBsAg carrier state characterised by the absence of HBeAg, 
presence of antiHBe, a persistently low or undetectable level of HBV DNA (<2000 IU/ml has 
been suggested) and normal ALT levels (Fattovich et al. 2008). If the patient remains in this 
phase, the outcome of the chronic infection is benign, with no resulting hepatic decompensation 
(Yim and Lok 2006). 
 
Immune escape phase/HBeAg-negative chronic hepatitis B 
 
However, some patients may progress to the next phase of chronic infection which is the 
reactivation/HBeAg-negative chronic hepatitis stage (Yim and Lok 2006). In this phase, the 
infection reactivates either spontaneously or due to immunosuppression of the patient with 
reversion to the HBeAg-positive state, or more commonly to an HBeAg-negative state due to the 
emergence of pre-core mutant strains of HBV which are unable to produce HBeAg (Fattovich et 
al. 2008). This phase is characterised by the absence of HBeAg, the presence of antiHBe along 
with continued varying degrees of liver inflammation and elevated but fluctuating ALT levels. 
HBV DNA levels may vary from 2000 to 20 million IU/ml (Fattovich et al. 2008). 
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Figure 2.6 Phases of chronic hepatitis B infection: serum and liver compartment. (Source: 
Dandri and Locarnini (2012) Reproduced with permission) 
ALT: alanine aminotransferase; cccDNA: covalently closed circular DNA; HBeAg: hepatitis B secreted e-antigen; HBsAg: 
hepatitis B surface antigen; HBV: hepatitis B virus; ORF: open reading frame; PC/C: precore/core; PE: Paul Ehrlich Institute; 
rcDNA: relaxed circular partially double-stranded DNA. 
  
Stellenbosch University http://scholar.sun.ac.za
 36 
 
Occult infection 
 
The detection of HBV DNA in serum in the absence of HBsAg is defined as an OBI and is 
thought to be due to control of the wild-type virus by the immune system rather than infection 
with a mutant strain of HBV (Dandri and Locarnini 2012; Hollinger and Good 2010). OBI has 
been associated with HBV transmission in organ transplants (Hollinger and Good 2010) and 
blood transfusions (Vermeulen et al. 2012) predominantly in the absence of antiHBs in the 
donated blood (Hollinger and Good 2010). OBI seems to be a risk factor for HCC development 
(Raimondo et al. 2007) although it is as yet unclear what mechanisms are involved (Zerbini et al. 
2008). In an occult infection, other markers such as antiHBc may or may not be detectable. 
 
HBV-related hepatocellular carcinoma 
 
Chronic infection with HBV is a risk factor for the development of liver cirrhosis and HCC 
(Beasley 1988). In endemic countries, chronic infection is mostly due to infection in childhood 
and in the subSahara, this leads to early development of HCC around the age of 45 years (Yang 
and Roberts 2010). 
 
The development of HBV-related HCC was originally thought to be the result of integration of 
the viral DNA into the host genome, but this integration does not target a specific part of the 
genome (Bruix and Llovet 2003) and other studies have suggested that this is not the actual 
mechanism behind hepatocarcinogenesis (Di Bisceglie 2009). Chronic infection may indirectly 
lead to HCC through continuous inflammation, scarring and repair of liver tissue leading to an 
increased turnover of hepatocytes and to the mutations in the genome which promote 
carcinogenesis (But et al. 2008). Recent studies have also directly implicated the HBx protein 
produced by the virus as having oncogenic properties (Bruix and Llovet 2003; Di Bisceglie 
2009; Kew 2011). The truncated MHBs antigen could also be involved in HCC development as 
it has transactivating properties (Blum and Moradpour 2002). 
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Certain genotypes of HBV have been linked to higher rates of HCC and in Asia, genotype C is 
thought to have a higher risk of HCC development than genotype B, but further studies are 
needed to clarify these associations (Di Bisceglie 2009). In South Africa, studies on genotype A 
have shown that infection with that particular genotype had a 4.5-fold higher risk of HCC 
development compared to infection with other genotypes (Kew et al. 2005). Another risk factor 
is gender; male patients have been shown to be two to seven times more likely to develop HCC 
than women (Yang and Roberts 2010).  
 
HIV-HBV co-infection 
 
HIV co-infection is known to influence the course of HBV infection. Chronic HBV infection 
occurs in 5% of immunocompetent adults whereas in HIV-infected adults, 25% of HIV-HBV co-
infections will become chronic (Lacombe et al. 2010). In co-infected patients not on therapy, due 
to the immunosuppression caused by HIV, HBV is able to replicate to high levels (Lacombe et 
al. 2010; Thio 2009) and in chronic infections, this has the potential to lead to early development 
of cirrhosis and HCC (Chen et al. 2006). Early ART for these patients is indicated (Brook et al. 
2010). 
 
MTCT of HBV in co-infected pregnant women is also an important issue. High viral loads in 
these patients will lead to MTCT of HBV (Burk et al. 1994) irrespective of immunization at birth 
(Lee et al. 1986). These women therefore need to be screened for HBsAg and HBeAg and if 
positive, they should be treated with a nucleos(t)ide analogue early in their third trimester to 
reduce their viral loads (Dusheiko 2012; Shi et al. 2010; Tran 2012). 
 
There are several nucleos(t)ide analogues such as lamivudine or tenofovir which can be used to 
treat both HBV and HIV monoinfections. However, lamivudine is rarely used alone to treat 
either infection because of its low genetic barrier to development of resistance in either HIV or 
HBV. A triple pol (rtV173L+rtL180M+rtM204V) mutant strain arising mainly after exposure to 
lamivudine (Lacombe 2010) leads to corresponding mutations in the surface gene 
(sE164D+sI195M) and has been shown to result in vaccine failure in chimpanzees (Kamili et al. 
2009).  
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The widespread use of ART to treat HIV has increased the life expectancy of HIV-infected 
individuals. It is therefore expected that more cases of HCC, one of the long-term consequences 
of HBV infection, will be seen in HIV-HBV co-infected patients (Lacombe 2010). 
 
 
2.6 MODES OF TRANSMISSION 
The virus is a blood-borne virus and any contact with contaminated blood or bodily fluids 
containing infected blood through the mucous membranes or broken skin could potentially result 
into transmission (Harrison, Dusheiko and Zuckerman 2009). 
 
Vertical transmission 
 
The virus can be transmitted from mother to child either in utero or during delivery and shortly 
after birth through the close contact between the infected mother and the neonate (perinatally). 
 
Although in utero transmission is rare, its occurrence is significantly associated with high 
maternal viral loads (Burk et al. 1994), a history of threatened preterm labour (Tran 2012), acute 
infection during the third term of pregnancy (Wood and Isaacs 2012) and can occur by the 
infection of endothelial cells of placenta capillaries and by cellular transfer from cell to cell (Xu 
D et al. 2002). Polymorphisms in cytokine genes have also been correlated with a susceptibility 
of intra-uterine HBV infection (Jonas 2009). This mode of transmission commonly results in 
infection of the neonate despite vaccination at birth (Lee et al. 1986) and is associated with the 
mother’s viral load irrespective of e-antigen status (Burk et al. 1994). 
 
Transmission at birth is possible when the baby is exposed to the blood and the genital secretions 
of the mother in the birth canal (Ranger-Rogez and Denis 2004). Breast-feeding is not contra-
indicated in mothers infected with HBV except if there is a possibility of exposure to maternal 
blood through cracked and bleeding nipples (Tran 2012). Although the virus is detected in breast 
milk, this has not been shown to result in HBV transmission (Hill et al. 2002; Wang et al. 2003). 
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Horizontal transmission in childhood 
 
Horizontal transmission is thought to be the most common route of transmission of HBV in 
childhood in subSaharan Africa either from sibling to sibling or between playmates (Whittle et 
al. 1983). Horizontal transmission in children is transmission which does not occur vertically or 
through sexual or parenteral routes (Davis, Weber and Lemon 1989). The routes of horizontal 
transmission have not yet been clearly identified although several potential routes have been 
investigated. 
 
One of the possible vehicles of transmission is saliva, which would explain how children 
transmit the virus from one another. Although saliva has been shown in gibbons to be infectious 
if injected (Bancroft et al. 1977), and high levels of HBV DNA have been found in the saliva of 
chronic carriers including children (Van Der Eijk et al. 2005), no studies have yet shown that 
oral exposure to saliva causes transmission of the virus. Transmission through bites from an 
infected person has been shown to occur (Stornello et al. 1991, Hui et al. 2005). This mode of 
transmission could be explained by the exposure of the blood of the uninfected person to the 
saliva of a chronic carrier known to carry a high viral load. Butler et al. (2010) showed that the 
mucosal surfaces and broken skin of children are commonly exposed to the saliva of their 
caregivers through various means including premastication of food and cleaning a cut/scrape on 
the children’s bodies with saliva. 
 
Other bodily fluids containing high levels of HBV DNA in infected individuals, including urine 
and sweat, have also been investigated but these have not been associated with transmission 
(Knutsson and Kidd-Ljunggren 2000; Van Der Eijk et al. 2005). A recent study showed that tears 
from a chronically infected baby could cause HBV infection in chimera mice (Komatsu et al. 
2012). 
 
In Africa, other modes of horizontal transmission could include ritual scarification and 
circumcision performed by a ‘witch-doctor’ or a traditional healer using unsterilized instruments 
(Kew et al. 1973). HBV virus is a sturdy virus capable of existing on surfaces for more than a 
week in the absence of visible blood, and still be infectious (Bond et al. 1981, Favero et al. 
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1974). Bedbugs have also been implicated as possible vehicles of transmission (Mayans et al. 
1990). 
 
Contact with infected bodily fluids 
 
In areas of low endemicity, the virus is mostly transmitted in the adult population, between drug 
users sharing needles and through sexual contact with an infected person (Alter 2003). 
 
Nosocomial infections are also possible especially among patients undergoing haemodialysis 
(Alter 2003). Improper sterilization of needles and reuse of disposable needles are also possible 
modes of transmission in hospital settings (Alter 2003). 
 
Infections through blood transfusions in South Africa are rare because of the recent introduction 
of individual-donation nucleic acid testing of blood in addition to serological testing to identify 
any potential OBI donors. However, if a donor is still in the window period of infection and is 
therefore negative for the tested markers, the donated blood has the potential of infecting the 
recipient (Vermeulen et al. 2012). 
 
Recently, a first report of reverse vertical transmission has been published. The authors reported 
that a mother was infected by her baby who had received a transfusion of contaminated blood. 
Phylogenetic analysis confirmed that the virus transmitted was homologous (Niederhauser et al. 
2012). 
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2.7 PREVENTION OF HBV INFECTION IN INFANTS 
 
Active immunisation 
 
HBV is a vaccine-preventable disease and a plasma-derived vaccine has been available since 
1980. A safe and effective second generation recombinant vaccine has also been available since 
1986 (WHO 2009), although it was only introduced to the South African EPI in 1995. The latter 
vaccine contains yeast-derived recombinant HBsAg with the immunogenic ‘a’ determinant 
(Clements et al. 2010). Third generation vaccines containing the PreS1 and PreS2 proteins in 
addition to HBsAg can elicit antibody responses in non-responders of the traditional vaccine 
(Harrison, Dusheiko and Zuckerman 2009). 
 
The WHO recommends the use of three doses of the vaccine in all infants: at birth, four weeks 
and ten weeks (WHO 2009). The efficacy of the vaccine has been demonstrated and the schedule 
recommended by the WHO has been shown to provide long-term immunity in healthy 
individuals (Viviani et al. 1999; van der Sande et al. 2006).  
 
Lee et al. (2006) calculated that infants who were born to HBsAg positive mothers but were 
vaccinated at birth were 3.5 times less likely to become infected with HBV. Administration of 
the vaccine later than a week after birth has been associated with an increased risk of MTCT of 
HBV infection (Marion et al. 1994; Ruff et al. 1995). 
 
In South Africa and in most of subSaharan Africa, the vaccine is administered at six, ten and 
fourteen weeks, a schedule which reflects the low risk of vertical transmission of HBV (Guidozzi 
et al. 1993) and the assumed predominance of horizontal transmission in infants (Botha et al. 
1986; Whittle et al. 1983).  
 
The vaccine is not contraindicated in HIV-infected infants and should be administered as soon as 
possible after birth with additional doses in non-responders. However, the levels of antiHBs in 
these infants should be monitored to ensure that they are adequately protected from HBV 
infection. It is recommended that immunocompromised individuals should be tested annually for 
Stellenbosch University http://scholar.sun.ac.za
 42 
 
levels of antiHBs and be revaccinated if these levels fall below the protective level of 10 IU/L 
(Kane et al. 2000). 
 
Hepatitis B immunoglobulin  
 
The hepatitis B immunoglobulin (HBIg) is a human immune globulin preparation with a high 
titre of antibody to hepatitis B surface antigen (antiHBs) used for passive immunoprophylaxis. 
Since it only provides immunity for about three months, it needs to be used as a supplement to 
the HB vaccine in preventing MTCT of HBV. 
 
The efficacy of using HBIg along with vaccination in infants at birth has been demonstrated. 
Beasley et al. (1983) showed that the combined use of HBIg and the birth dose of the vaccine 
was 94% effective in preventing MTCT compared to an efficacy of only 71% and 75% if HBIg 
and vaccine respectively were used alone. 
 
However, the benefit of using HBIg in infants born to mothers who are infected with precore 
mutant strains of HBV may be limited in preventing vertical transmission of the virus (Yang et 
al. 2003) but may reduce the risk of fulminant hepatitis in these newborns (Chen et al. 2004). 
 
The use of HBIg in the third trimester of pregnancy has been previously reported to significantly 
reduce the rate of transmission of HBV in HBeAg-positive mothers (Xiao et al. 2007). However, 
another study found no benefit in using HBIg before birth in HBeAg-positive mothers (Yuan et 
al. 2006). 
 
In subSaharan Africa, HBIg is not available for PMTCT because of the costs involved and 
because vertical transmission of HBV is not considered to be a major health problem. 
 
Role of antivirals in the prevention of MTCT 
 
The use of either vaccine or HBIg or both will not however prevent MTCT if the mother’s viral 
load is high (Burk et al. 1994; Lee et al. 1986). HBV infected pregnant women with high viral 
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loads need to be started on antiHBV therapy during pregnancy. HIV-HBV co-infected mothers 
with low CD4 counts are less likely to clear HBeAg (Lacombe et al. 2010; Thio 2009), and have 
high viral loads, making them at risk of transmitting HBV to their children. 
 
The use of a nucleos(t)ide analogue to reduce the HB viral loads of the mothers during 
pregnancy in conjunction with vaccination of the baby will lower the risk of MTCT of HBV 
(Dusheiko 2012). Xu et al. (2009) showed that transmission of HBV was significantly decreased 
by the use of lamivudine when compared to the placebo group. The same has been reported by 
another group (van Zonneveld 2003). 
 
However, given the rapid emergence of drug resistance mutations from lamivudine 
monotherapy, it is not recommended for use alone in the prevention of MTCT. In treating both 
mono and co-infections, the drug of choice is tenofovir. So far clinical trials have not looked at 
the efficacy of tenofovir in preventing MTCT of HBV. However, a retrospective study has 
shown that the use of tenofovir significantly reduced the viral loads in HBV-infected mothers 
and none of their infants were positive for HBsAg at 28-36 weeks after delivery (Pan et al. 
2012). 
 
Infants may be exposed to tenofovir through breastfeeding but the concentration secreted in 
breastmilk is low. There is a potential risk of bone density and renal problems in neonates who 
are exposed to tenofovir, but the benefits are thought to outweigh the risks (Kew et al. 2011). 
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CHAPTER THREE: MATERIALS AND METHODS 
3.1 ETHICAL APPROVAL 
Ethics Approval was received from the Health Research Ethics Committee of Stellenbosch 
University on the 31
st
 of May 2011 for a period of one year (Ethics reference number: 
N11/05/151). This was renewed in May 2012 for an additional year. 
 
 
3.2 SAMPLE AND DATA COLLECTION 
Residual samples submitted to the National Health Laboratory Service (NHLS) Division of 
Medical Virology, Tygerberg Hospital, for HIV-1 screening PCR tests were included in this 
cross-sectional study. These samples were collected from HIV-exposed children between the 
ages of 0 and 18 months. Samples which conformed to the following criteria were included: 
 
1. children residing in the Western Cape; 
2. conclusive HIV-1 DNA PCR and HIV-1 RNA PCR results were available and 
3. residual sample volume was at least 100 µl. 
 
The chosen samples were centrifuged at 1400 relative centrifugal force (RCF) for ten minutes. 
The isolated plasma was transferred to a 1.5ml microcentrifuge tube before being 
chronologically relabeled to de-identify each sample to meet ethical requirements. Plasma 
samples were stored at -20 °C until further testing. 
 
Also in accordance with ethical guidelines, personal patient information and laboratory 
identification numbers were stored in a password-protected digital database, which was separate 
from the study data. However, for demographic analytical purposes, information on the age, sex, 
and HIV status of the patients, where available, was documented. Since information about the 
race of these patients was not regularly available, this criterion was excluded from further study 
analyses. 
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3.3 SCREENING PROCESS AND FOLLOW-UP OF POSITIVE SAMPLES 
The samples were initially tested for HBsAg and confirmed with an HBsAg neutralisation assay. 
In parallel to serological testing, the first 600 HBsAg negative samples were tested for HBV 
DNA. Very few OBIs (presence of HBV DNA in the absence of HBsAg) were expected. 
Therefore, HBsAg negative samples which had more than 150µl of plasma were pooled and 
extracted together. Any pooled samples found to have a detectable viral load using real-time 
PCR, were extracted individually and tested as individual samples. HBsAg negative samples 
with less than 150µl of plasma and HBsAg positive samples were extracted independently.  
 
The names and contact details of the infants whose samples were found to be HBsAg and/or 
DNA positive were retrieved from the digital database. The mothers of these infants were 
contacted through their respective clinics and a blood sample was collected on the same day 
from each mother-infant pair. The blood samples were dispatched to the Division of Medical 
Virology, Tygerberg, where they were centrifuged and the plasma collected was stored at -20°C 
until further testing. The followed-up mother-child pairs are collectively called ‘patients’ 
henceforth. The patients were first tested for HBsAg, and the positive results confirmed by an 
HBsAg neutralization test using antiHBs. Confirmed HBsAg positive patients were tested for 
HBeAg/antiHBe and HBsAg negative patients were tested for antiHBs where possible. All 
followed-up patients were also tested for HBV DNA and antibody to hepatitis B core antigen 
(antiHBc). HBV DNA positive samples were sequenced where possible. 
 
Patients who tested positive for HBsAg and/or HBV DNA on follow-up were referred to a 
hepatologist collaborating on this project from Tygerberg Hospital for further management. 
  
Stellenbosch University http://scholar.sun.ac.za
 46 
 
3.4 SEROLOGICAL TESTING 
3.4.1 SCREENING FOR HBsAg AT SCREENING STAGE AND FOLLOW UP 
Principle 
 
The Murex HBsAg Version 3 assay (Murex Biotech Ltd, Dartfort, United Kingdom (UK)) 
qualitatively tests for the presence of HBsAg in plasma and serum samples of human origin. The 
microtitre plate wells from the kit are pre-coated with mouse monoclonal antibodies which bind 
specifically to a primary epitope of HBsAg. Following the principle of a sandwich Enzyme 
Linked Immuno Sorbent Assay (ELISA), any HBsAg that was present in the sample would first 
bind to the pre-coated antibody. An antibody labeled with the enzyme Horse Radish Peroxidase 
(HRP) would then be added to the wells and would bind to a secondary epitope of the captured 
HBsAg, creating an antibody/antigen/antibody-enzyme complex. In the absence of HBsAg in the 
plasma sample, there would be no complex formation. The addition of an enzyme colorimetric 
substrate would cause a colour change. This substrate solution contained 3,3’, 5,5’-
tetramethylbenzidine (TMB) and hydrogen peroxide which could be oxidized in a reaction 
catalysed by the enzyme bound in the complex, causing a colour change to purple in the positive 
wells. There would be a final colour change to yellow in the wells after addition of a stop 
solution (0.5 M H2SO4). A sample which was negative for HBsAg would remain colourless after 
the addition of the substrate and stop solutions. 
 
Method 
 
Samples were first diluted 1:4 with normal human plasma (NHP) provided by the Western 
Province Blood Transfusion Service known to be negative for all HBV markers. This dilution 
method has been previously validated in this laboratory (Maponga TG, MSc Thesis, Stellenbosch 
University, 2012) and was done because of the limited amount of plasma available for testing. 
 
The samples were first incubated for 60 minutes in the wells at 37
o
C with a sample diluent. A 
solution containing a goat anti-human antibody specific for HBsAg was then added to the wells 
and the microtitre plate was incubated for 30 minutes at 37
o
C. The microtitre plate was then 
washed five times using an automatic plate washer. Immediately after the washing step, 100µl of 
Stellenbosch University http://scholar.sun.ac.za
 47 
 
a substrate solution was added to each well. The final step in this assay was the addition of 50µl 
of the stop solution. The colour intensity of each well was measured spectrophotometrically 
using a dual wavelength Anthos HT3 Microtiter Plate Reader (Anthos Labtec Instruments 
GmbH, Salzburg, Austria) at 450 nm, using 650 nm as the reference wavelength, within 15 
minutes of the addition of the stop solution. 
 
Validation of results 
 
To validate each test batch, two negative controls, as well as a positive control (provided by the 
manufacturer) were included in each run. An in-house working control known to be positive for 
HBsAg was also included in each run. For the run to be considered valid the mean absorbance 
value of the negative controls had to be less than 0.15 and the absorbance value of the positive 
control had to be greater than 0.8 above the mean of the negative controls.  
 
Calculation of results 
 
Once the microtitre plate was read, an average was calculated using the absorbance of the 
negative control wells. A value of 0.05 was added to obtain a cut off. Only samples which 
exceeded this threshold were considered to be positive. 
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3.4.2 CONFIRMATION TEST FOR HBsAg POSITIVES 
Principle 
 
Samples were confirmed as being HBsAg positive by neutralization. This in-house test was 
performed with the Murex HBsAg Version 3 Assay and antiHBs-positive plasma obtained from 
the Blood Borne Viruses Unit (BBVU), Health Protection Agency (HPA), London. 
 
Each sample was diluted 1:2 with two different diluents. One diluent contained the antiHBs 
antibodies and one diluent was the NHP known to be negative for all HBV markers. These tubes 
were then incubated overnight and tested the following day for HBsAg. The principle of the test 
is that the tube containing NHP and the sample would show a certain optical density (OD) which 
would be above the cut off threshold making the sample positive for HBsAg. In the tube with 
antiHBs positive plasma and the sample however, the antibodies would bind to the HBsAg to 
form immune complexes. These complexes would not be detected on the Murex HBsAg assay 
and the wells with the antiHBs would therefore show a reduced OD. 
 
Method 
 
The sample itself was first diluted 1:2 using NHP. Next, 50µl of antiHBs-positive plasma and 
50µl of NHP were added to two separate tubes respectively, followed by 50µl of the diluted 
sample. This resulted in a final sample dilution of 1:4. The tubes were vortexed, centrifuged and 
incubated for at least 16 hours at 37°C. After the overnight incubation, the samples were tested 
for HBsAg using the Murex HBsAg Version 3 Assay as described above in section 3.5.1. 
One sample had a low volume of plasma left and a 1:4 dilution was first done on the sample and 
then 50µl of this dilution was added to 50µl of NHP and 50µl of antiHBs so that the final 
dilution factor was eight. 
 
Some of the followed-up plasma samples had OD values which were above the detection range 
of the spectrophotometer. These samples were diluted 1:10
4
 before an observable reduction in 
OD could be seen. 
  
Stellenbosch University http://scholar.sun.ac.za
 49 
 
Validation of results 
 
To validate each test batch, two negative controls, as well as a positive control (provided by the 
manufacturer) were included in each run. An in-house working control known to be positive for 
HBsAg was also included in each run. For the run to be considered valid the mean absorbance 
value of the negative controls had to be less than 0.15 and the absorbance value of the positive 
control had to be greater than 0.8 above the mean of the negative controls. 
 
Calculation of results 
 
Once the microtitre plate was read, an average was calculated using the absorbance of the 
negative control wells. A value of 0.05 was added to obtain a cut off. Only samples which 
exceeded this threshold were considered to be positive. 
 
Neutralization is defined as a reduction of at least 50% between the absorbance values obtained 
with and without addition of antiHBs positive plasma. Samples which were neutralized were 
considered to be true HBsAg positives. 
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3.4.3 HBeAg TESTING OF HBsAg POSITIVE SAMPLES 
Principle 
 
All followed-up patient plasmas which were confirmed HBsAg positive were tested for HBeAg. 
HBeAg is a marker associated with high viral loads. The ETI-EBK PLUS kit from Diasorin 
(Diasorin, Saluggia, Italy) qualitatively tests for the presence of HBeAg in plasma and serum 
samples of human origin. The microtitre wells from the kit are pre-coated with mouse 
monoclonal antibodies which bind specifically to HBeAg. Following the principle of a sandwich 
ELISA, any HBeAg that was present in the sample would first bind to the pre-coated antibody. 
An antibody labeled with the enzyme HRP would then be added to the wells and would bind to a 
secondary epitope of the captured HBeAg, creating an antibody/antigen/antibody-enzyme 
complex. In the absence of HBeAg in the plasma sample, there would be no complex formation. 
The addition of an enzyme colorimetric substrate would cause a colour change. This substrate 
solution contained TMB and hydrogen peroxide which could be oxidized in a reaction catalysed 
by the enzyme bound in the complex, causing a colour change to blue in the positive wells. 
There would be a final colour change to yellow in the wells after addition of a stop solution (0.4 
N H2SO4). A sample which was negative for HBeAg would remain colourless after the addition 
of the substrate and stop solutions. 
 
Method 
 
The samples were first incubated for 120 minutes in the wells at 37
o
C with 50µl of an incubation 
buffer. The plate was then washed five times to remove any excess sample using an automatic 
plate washer.  Next, 100µl of an enzyme tracer was added to the wells and the microtitre plate 
was incubated for 60 minutes at 37
o
C. The microtitre plate was once more washed five times 
using an automatic plate washer. Immediately after the washing step, 100µl of a substrate 
solution was added to each well and incubated at room temperature for 30 minutes away from 
direct light. The final step in this assay was the addition of 100µl of the stop solution. The colour 
intensity of each well was measured spectrophotometrically using a dual wavelength Anthos 
HT3 Microtiter Plate Reader (Anthos Labtec Instruments GmbH, Salzburg, Austria) at 450 nm, 
using 650 nm as the reference wavelength. 
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Validation of results 
 
To validate each test batch, three calibrator controls, one negative control, as well as a positive 
control (provided by the manufacturer) were included in each run. An in-house working control 
known to be positive for HBeAg and a blank well containing only the substrate solution were 
also included in each run. 
 
For a run to be considered valid, the following criteria needed to be met: 
1. The absorbance value for the blank well was between 0.000 and 0.150. 
2. The absorbance of each calibrator and the negative control and the mean absorbance of 
the 3 calibrators were greater than -0.020 and less than 0.120. 
3. The absorbance of the positive control was greater than 0.500 and less than 2.500. 
4. The difference between the absorbance of the positive control and the negative control 
was greater than 0.450. 
 
Calculation of results 
 
The cut off value of the run was calculated by subtracting the absorbance of the blank from the 
mean absorbance of the calibrator control values and adding 0.060. Samples with an absorbance 
of 10% or more above that of the cut off were considered to be positive. 
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3.4.4 AntiHBe TESTING OF HBsAg-POSITIVE SAMPLES 
Principle 
 
All HBsAg-positive samples were tested for antiHBe. AntiHBe is a marker of recovery and is 
present in the blood along with HBeAg when HBeAg seroconversion is imminent. The ETI-EBK 
AB PLUS kit from Diasorin (Diasorin, Saluggia, Italy) qualitatively tests for the presence of 
HBeAg in serum and plasma samples of human origin. The microtitre wells from the kit are pre-
coated with mouse monoclonal antibodies which bind specifically to a primary epitope of 
HBeAg. A neutralization buffer containing recombinant HBeAg was added to the samples. 
Following the principle of a competitive ELISA, any free antiHBe in the sample would compete 
with the immobilized antiHBe for the HBeAg in the buffer. An antibody labeled with the enzyme 
HRP would then be added to the wells. In the absence of antiHBe in the samples, this antibody 
would bind to a secondary epitope of the captured HBeAg in the microwells, creating an 
antibody/antigen/antibody-enzyme complex. The amount of complex formation would be 
inversely proportional to the amount of antiHBe in the sample. The addition of an enzyme 
colorimetric substrate would cause a colour change. This substrate solution contained TMB and 
hydrogen peroxide which could be oxidized in a reaction catalysed by the enzyme bound in the 
complex, causing a colour change to blue in the wells negative for antiHBe. The addition of a 
stop solution (0.4N H2SO4) would cause a final colour change to yellow in the negative wells. A 
sample which was positive for antiHBe would remain colourless after the addition of the 
substrate and stop solutions. 
 
Method 
 
Fifty microlitres of each sample was first incubated for 120 minutes in the wells at 37
o
C with 
50µl of an incubation buffer and 50µl of a neutralization buffer. The plate was then washed five 
times to remove any excess sample and recombinant HBeAg using an automatic plate washer.  
Next, 100µl of an enzyme tracer containing mouse monoclonal antibody specific for HBeAg was 
added to the wells and the microtitre plate was incubated for 60 minutes at 37
o
C. The microtitre 
plate was once more washed five times using an automatic plate washer. Immediately after the 
washing step, 100µl of a substrate solution was added to each well and incubated at room 
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temperature for 30 minutes away from direct light. The final step in this assay was the addition 
of 100µl of the stop solution. The colour intensity of each well was inversely proportional to the 
amount of antiHBe in a sample and was measured spectrophotometrically using a dual 
wavelength Anthos HT3 Microtiter Plate Reader (Anthos Labtec Instruments GmbH, Salzburg, 
Austria) at 450 nm, using 650 nm as the reference wavelength. 
 
Validation of results 
 
To validate each test batch, three calibrator controls, one negative control, as well as a positive 
control, provided by the manufacturer, were included in each run. A blank well containing only 
the substrate solution was also included in each run. 
 
For a run to be considered valid, the following criteria needed to be met: 
1. The absorbance value for the blank well was between 0.000 and 0.150. 
2. The absorbance of each calibrator and the negative control and the mean absorbance of 
the 3 calibrators were greater than 0.500 and less than 2.500. 
3. The absorbance of the positive control was greater than 0.050 and less than 0.300. 
4. The difference between the absorbance of the negative control and the positive control 
was greater than 0.250. 
 
Calculation of results 
 
The cut off of the run was calculated by subtracting the absorbance of the blank from the mean 
absorbance of the calibrator values and multiplying it by 0.500. Samples with an absorbance of 
10% or less below that of the cut off were considered to be positive. 
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3.4.5 AntiHBc TESTING OF ALL FOLLOWED-UP SAMPLES 
Principle 
 
The follow-ups were also tested for antiHBc which is a marker of past infection. The Murex 
antiHBc (total) assay (Murex Biotech Ltd, Dartfort, UK) qualitatively tests for the presence of 
total antiHBc in serum and plasma samples of human origin. The microtitre plate wells from the 
kit are pre-coated with recombinant hepatitis B core antigen (HBcAg). Following the principle of 
a competitive ELISA, any antiHBc that was present in the sample would first bind to the pre-
coated recombinant HBcAg in the wells. In the absence of antiHBc in the sample, an antibody 
labeled with HRP would bind to the HBcAg coated on the wells, creating an 
antibody/antigen/antibody-enzyme complex. On the other hand, if antiHBc was present in the 
plasma sample, there would be no or little complex formation with the coated antigen. The 
addition of an enzyme colorimetric substrate would cause a colour change. This substrate 
solution contained TMB and hydrogen peroxide which could be oxidized in a reaction catalysed 
by the enzyme bound in the complex, causing a colour change to blue/green in the wells negative 
for antiHBc. The addition of a stop solution would cause a final colour change to yellow in the 
negative wells. A sample which was positive for antiHBc would remain colourless after the 
addition of the substrate and stop solutions. 
 
Method 
 
The samples were first incubated for 30 minutes in the wells at 37
°
C with a sample diluent. The 
addition of a sample to the green sample diluent changed its colour to blue. The microtitre plate 
was then washed five times using an automatic plate washer and immediately after washing, a 
solution containing antibody specific for HBcAg was added to the wells, and the microtitre plate 
was incubated for half an hour at 37
o
C. The microtitre plate was then washed another five times 
using an automatic plate washer and immediately after washing, 100µl of a substrate solution 
was added to each well and the plate was incubated for another half an hour in the dark at 37°C. 
The final step in this assay was the addition of 50µl of a stop solution, 0.5M H2SO4. The colour 
intensity of each well was inversely proportional to the concentration of antiHBc in the sample 
and was measured spectrophotometrically using a dual wavelength Anthos HT3 Microtiter Plate 
Stellenbosch University http://scholar.sun.ac.za
 55 
 
Reader (Anthos Labtec Instruments GmbH, Salzburg, Austria) at 450 nm, using 650 nm as the 
reference wavelength, within 15 minutes of the addition of stop solution. 
 
Validation of results 
 
To validate each test batch, two negative controls and two positive controls, provided by the 
manufacturer, were included in each run. An in-house working control known to be positive for 
antiHBc was also included in each run. The mean absorbance of the positive controls had to be 
below 0.24 and the difference between the mean absorbance value of the negative controls and 
the mean absorbance value of the positive controls had to be between 0.5 and 2.2 for the run to 
be considered valid. 
 
Calculation of results 
 
The cut off value was calculated by adding the mean absorbance of the positive controls to the 
mean absorbance of the negative controls and dividing this value by two. Only samples which 
had an absorbance value below this threshold were considered to be positive. 
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3.4.6 AntiHBs TESTING OF HBsAg NEGATIVE SAMPLES 
Principle 
 
Samples which were HBsAg negative were tested for antiHBs. AntiHBs is a marker of recovery 
from an HBV infection and will normally be detected in the blood after HBsAg has disappeared 
although there is a window period between the disappearance of HBsAg and the appearance of 
antiHBs. AntiHBs is also produced by the immune system in response to the administration of 
the hepatitis B vaccine. The ETI-EBK AB PLUS kit from Diasorin (Diasorin, Saluggia, Italy) 
was used to qualitatively test for the presence of antiHBs in serum and plasma samples of human 
origin. The microtitre wells from the kit are pre-coated with human HBsAg and any antiHBs in a 
sample would bind to a primary epitope of the coated HBsAg. Then, HBsAg labeled with HRP 
would be added and the captured antiHBs would bind to a secondary epitope of the labeled 
HBsAg creating antigen/antibody/antigen-enzyme complexes in the microwells of the positive 
samples. In the absence of antiHBs in the plasma sample, there would be no complex formation. 
The addition of an enzyme colorimetric substrate would cause a colour change. This substrate 
solution contained TMB and hydrogen peroxide which could be oxidized in a reaction catalysed 
by the enzyme bound in the complex, causing a colour change to blue in the positive wells. 
Lastly, a blocking reagent (1N H2SO4) would be added causing a final colour change to yellow 
in the wells positive for antiHBs. A sample which was negative for antiHBs would remain 
colourless after the addition of the substrate and stop solutions. 
 
Method 
 
One hundred microlitres of each sample was first incubated for 120 minutes in the wells at 37
o
C 
with 100µl of an incubation buffer. The plate was then washed five times to remove any excess 
sample. Then, 100µl of an enzyme tracer containing HBsAg was added to the wells and the 
microtitre plate was incubated for an hour at 37
o
C. The microtitre plate was once more washed 
five times using an automatic plate washer. Immediately after the washing step, 100µl of a 
substrate solution was added to each well and incubated at room temperature for 30 minutes 
away from direct light. The final step in this assay was the addition of 200µl of a blocking 
reagent. The colour intensity of each well was proportional to the amount of antiHBs in a sample 
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and was measured spectrophotometrically using a dual wavelength Anthos HT3 Microtiter Plate 
Reader (Anthos Labtec Instruments GmbH, Salzburg, Austria) at 450 nm, using 650 nm as the 
reference wavelength. 
 
Validation of results 
 
To validate each test batch, three calibrator controls (two of Calibrator 1 and one of Calibrator 2) 
and two negative controls provided by the manufacturer, were included in each run. An in-house 
working control containing 10 IU/L of antiHBs and a blank well containing only the substrate 
solution were also included in each run. 
 
For a run to be considered valid, the following criteria must have been met: 
1. The absorbance value for the blank well must be between 0.000 and 0.150. 
2. The mean absorbance of the negative control must be less than 0.100. 
3. The mean absorbance of Calibrator 1 must be greater than 0.035 and less than 0.300. 
4. The ratio of the mean absorbance for Calibrator 1 to the mean absorbance for the 
negative control must be greater than or equal to 2.0. 
5. The ratio of the mean absorbance for Calibrator 2 to the mean absorbance for Calibrator 1 
must be greater than or equal to 4.5. 
 
Calculation of results 
 
Calibrator 1 contains antiHBs in the concentration of 10 IU/L. Since a value of more than 10 
IU/L is generally considered to be protective, the absorbance value observed with Calibrator 1 
was taken to be the cut off. Therefore, samples which had an absorbance greater than or equal to 
the absorbance observed in the wells containing Calibrator 1 were considered to be positive for 
antiHBs.  
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3.4.7 QUALITY CONTROL FOR SEROLOGICAL ASSAYS 
The addition of each reagent was marked by a colour change which ensured that no wells were 
missed. 
 
To ensure that there was no carry-over contamination between wells, separate tips were used to 
pipette individual samples and reagents into the respective wells. The tubes with the plasma 
samples were briefly centrifuged before testing to eliminate the risk of aerosol formation from 
any droplets on the inside of the caps. In addition to the manufacturer’s controls, an additional 
in-house working control which was positive for the marker under test (except for antiHBe) was 
included with each run to ensure that Westgard’s rules of quality control were being followed. 
 
For the neutralization in-house assay, in addition to the above, control tubes with antiHBs alone, 
NHP alone, antiHBs and NHP together were also incubated along with the samples. They acted 
as negative controls to ensure that there was no cross-reactivity between reagents which could 
have resulted in false positives. A working control known to be HBsAg positive was also tested 
in the same way as the samples to ensure the assay was working properly. 
 
An automatic washer was used for the washing steps and was cleaned with autoclaved Milli-Q 
grade water and primed with washing buffer before each run. After each run, the washer was 
again washed with autoclaved Milli-Q grade water to prevent blocking of the system with salts 
from the washing buffer. 
 
In any cases where a run did not meet the manufacturer’s validation criteria, the results were 
considered to be invalid and the test was repeated for those samples.  
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3.5 MOLECULAR TESTING 
3.5.1 DNA EXTRACTION OF SAMPLES 
3.5.1.1 INDIVIDUAL VIRAL DNA EXTRACTIONS 
The HBsAg positive samples were first diluted 1:4 with NHP known to be negative for HBV 
markers due to limited sample volumes. The QIAamp® Min Elute® Virus Spin Kit (QIAGEN, 
Germany) was used to extract DNA from the samples. The minimum amount of plasma required 
for the test using this kit was 200µl. 
 
A lysis buffer containing 1µg/µl of carrier RNA (provided with the kit) and an internal control 
[400 copies/µl of murine cytomegalovirus (mCMV)] was freshly prepared before each 
extraction. The mCMV was obtained from the BBVU, HPA (Colindale, UK). The extraction was 
then performed according to the manufacturer’s instructions with some minor modifications 
described by Garson et al. (2005) and the DNA eluted in 65µl of elution buffer provided with the 
kit. 
 
Ten-fold dilutions were made of a patient sample with a known viral load of 10
8
 IU/ml. The kit 
was then used to extract dilutions of 10
7
 IU/ml to 10
1
 IU/ml and eluted in 65µl of elution buffer. 
These dilutions (henceforth referred to as real-time PCR standards) were subsequently used to 
construct a standard curve. 
 
3.5.1.2 VALIDATION OF POOLING ASSAY FOR VIRAL DNA EXTRACTIONS 
The limit of detection of the real-time PCR assay, DL IU/ml, was determined first. A patient 
sample of known HBV viral load (10
8
 IU/ml) was diluted to 250 IU/ml and 100 IU/ml of HBV. 
One-fold dilutions were made from these two stock concentrations as shown in Table 3.1 and 
termed ‘working dilutions’. These working dilutions were extracted and run in duplicate on three 
different days using a real-time PCR protocol described elsewhere (in section 3.5.2). The viral 
loads corresponding to the lowest dilution detectable in all three runs were thus deduced to be DL 
IU/ml. 
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Table 3. 1Dilutions of stock solutions of 250 IU/ml, 100IU/ml and PL IU/ml 
 
Neat 1:2 1:3 1:4 1:5 1:6 1:8 1:10 1:20 1:25 
NHP/ µl 0 100 133.3 150 160 166.7 175 180 190 192 
Neat/ µl 200 100 66.7 50 40 33.3 25 20 10 8 
From the stock solution of 100 IU/ml, working dilutions until 1:10 were made and extracted and from the stock 
solution of PL IU/ml, dilutions until 1:6 were made and extracted. 
 
 
The real-time assay would be used to detect the viral load in a batch of four pooled samples of 
50µl each. The viral load in any positive sample in a batch would thus be diluted by a factor of 
four. DL IU/ml was therefore multiplied by four to theoretically determine the limit of detection, 
PL IU/ml, for a pooling assay. To confirm this, the 10
8
 IU/ml sample was diluted to obtain a 
stock solution containing PL IU/ml of HBV. One-fold dilutions were made from the working 
solution containing PL IU/ml as shown in Table 3.1 and were tested in duplicate on three 
different days using a real-time PCR protocol described elsewhere (section 3.5.2). The viral load 
corresponding to a dilution of 1:4 needed to be detectable in all three runs for PL IU/ml to be 
confirmed as the detection limit of the pooling assay. The pooling protocol was then employed to 
screen batches of four, pooled, 50µl, HBsAg negative samples for HBV DNA as described 
elsewhere (sections 3.5.1.3 and 3.5.2). 
 
3.5.1.3 POOLED VIRAL DNA EXTRACTIONS 
DNA was extracted from the pooled samples, as described for the individual extractions in 
section 3.5.2. The only change to the protocol was in the first step where 50µl of plasma from 
four different samples (giving a total volume of 200µl) was added to 25µl of Proteinase K in a 
1.5ml microcentrifuge tube followed by 200µl of the lysis buffer. 
 
Furthermore, if HBV DNA was detected in a batch of pooled samples, the four samples making 
up the positive pool were extracted individually as described under section 3.5.1.1 and tested for 
HBV DNA by real time PCR as described under section 3.5.2. 
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3.5.2 VIRAL LOAD TESTING USING REAL-TIME PCR 
A multiplex, hydrolysis probe-based, real-time PCR assay, with mCMV as an internal control, 
described by Garson et al. (2005) was used to calculate the viral loads of the samples. The assay 
was validated for DNA quantification using a final reaction volume of 25µl on the RotorGene™ 
6000 (Corbett Life Science, Australia) in this laboratory (Maponga TG, MSc Thesis, 
Stellenbosch University, 2012), and is based on the in-house real-time HBV assay used at the 
BBVU, HPA London (http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684). 
 
The HBV primers and probe used in this assay target highly conserved sequences in the HBsAg 
gene. The mCMV primers and probe target regions specific to mCMV and were not expected to 
cross-react with sequences from other species. The probes used a TAMRA quencher and VIC 
and FAM as the reporter dyes. FAM has an emission wavelength of 517nm which can be 
detected by the green channel of the real-time thermocycler and was used for the detection of 
HBV. VIC was detected by the yellow channel of the real-time thermocycler as its emission 
wavelength is 554nm and was used to detect mCMV. As described in section 3.5.1.1, previously 
extracted real-time PCR standards were used to construct a standard curve against which the 
viral loads of the samples were calculated. 
 
The primer and probe sequences are listed in Table 3.2. 
 
Table 3. 2 List of primer and probe sequences used for HBsAg gene real-time PCR assay 
Target Primer sequence 
HBV_Forward 5′-GTG TCT GCG GCG TTT TAT CA-3′ 
HBV_Reverse 5′- GAC AAA CGG GCA ACA TAC CTT-3′ 
HBV_Probe 5′FAM-CCT CT(T/G) CAT CCT GCT GCT ATG CCT CAT C-3′-TAMRA 
mCMV_Forward 
Primer 
5′-AAC CCG GCA AGA TTT CTA ACG-3′ 
mCMV_Reverse 
Primer 
5′-ATT CTG TGG GTC TGC GAC TCA -3′ 
mCMV_Probe 5′-VIC-CTA GTC ATC GAC GGT GCA CAT CGG C-3′TAMRA 
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Method 
 
The master mix was prepared for the appropriate number of samples, controls and standards (in 
duplicate), using the volumes and concentrations for each reagent given in Table 3.3 including a 
2x SensiMix Probe Kit II buffer from Bioline (Bioline, GmbH, Germany). Next, 15µl of the 
master mix was distributed in individual 0.2ml PCR tubes and ten µl of DNA extract from each 
sample or standard was added to their respective tube so that the final reaction volume was 25µl. 
The cycling parameters of the PCR reaction given in Table 3.4 were used. 
 
Table 3. 3 Master mix composition for surface gene real-time PCR assay 
Reagent Starting Concentration 
Volume/µl   
x1 
Final Concentration 
SensiMix Buffer 2x 12.50 1x 
HBV_Forward 
Primer 
100 µM 0.10 400 nM 
HBV_Reverse 100 µM 0.10 400 nM 
HBV_Probe 100 µM 0.05 200 nM 
mCMV_Forward 100 µM 0.10 400 nM 
mCMV_Reverse 100 µM 0.10 400 nM 
mCMV_Probe 100 µM 0.05 200 nM 
Water n/a 2.00 n/a 
Total volume n/a 15.00 n/a 
n/a: not applicable 
 
 
Table 3. 4 Cycling parameters for surface gene real-time PCR assay 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 15 minutes 
Denaturation 
45 cycles 
95°C 15 seconds 
Annealing/Extension 60°C 60 seconds 
 
 
After the completion of each run, results were analysed using the Rotor-Gene 6000 Series 
Software 1.7 (Corbett Life Sciences, Australia). 
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Validity of results 
For a run to be considered valid, the following criteria needed to be met: 
1. There was no detectable viral load in the negative controls (NHP) and the NTC. 
2. The standard curve used to calculate viral loads was valid. This was given by:  
a. An R2 value of between 0.9 and 1.1. The R2 is a measure of how reliable the 
results are.  
b. An M value of between 3.1 and 3.4. The M is used to calculate the efficiency of 
the reaction, 
c. The cycle threshold (Ct) values of the standards and the samples (the point where 
the amplification curve crosses the threshold and which was used to calculate the 
viral load in the sample from the standard curve) was less than the value of B. B 
was the highest cycle number at which the viral load obtained from the graph was 
considered to be reliable. If a sample crossed the detection threshold after cycle 
number B, its viral load was not calculated by the software. 
The values of R
2
, M and B were automatically calculated by the software and displayed next to 
the standard curve. The threshold was manually adjusted in certain cases to obtain satisfactory 
values for the M and R
2
. 
 
Calculation of results 
Since each sample was diluted four times before being extracted, the viral load given by the 
above method was multiplied four fold to calculate the viral load in the original sample.  
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3.5.3 SEQUENCING OF POL/SURFACE GENE REGION OF HBV DNA POSITIVE 
SAMPLES 
Principle 
 
The pol/surface genomic region of the HBV strains was sequenced in DNA-positive samples 
using a protocol established by the BBVU, HPA (Colindale, London) which has since been 
established in this laboratory  
(http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684). 
 
The steps followed for the sequencing can be summarized as follows: Two rounds of 
conventional PCR were performed on the DNA positive samples. The PCR products were then 
electrophoresed on an agarose gel to ensure that sufficient quantities of the target DNA fragment 
had been amplified to be sequenced. This would be indicated by the presence of a crisp thick 
band of the expected size for each sample. The PCR products were purified and subjected to a 
cycle sequencing reaction. The sequencing reaction product was cleaned and loaded on a 
capillary sequencer to be analysed. 
 
Method 
 
Pre-nested PCR 
 
A pre-nested PCR was performed on the DNA extracts of the HBV DNA-positive samples. The 
primers shown in Table 3.5 were used and the master mix for the PCR reaction was prepared 
using the reagents listed in Table 3.6. 
 
Table 3. 5 Primers used for pre-nested PCR of pol/surface region 
Name Sequence 
Binding position 
from Eco R1 site 
HBV Z_Forward 5′- AGC CCT CAG GCT CAG GGC ATA -3′ 3134 – 3154 
HBV 3_Reverse 5′- CGT TGC CKD GCA ACS GGG TAA AGG -3′ 1170 – 1146 
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Table 3. 6 Master mix for pre-nested PCR of pol/surface region 
Reagents 
Starting 
Concentration 
Volume/µl 
x1 
Final 
Concentration 
PCR Buffer 10x 2.50 1x 
MgCl2 50mM 0.75 1.5mM 
dNTPs* 10mM 0.50 0.2mM 
Taq Polymerase  0.10  
HBV 3 20pmol/µl 0.50 0.4pmol/µl 
HBV Z 20pmol/µl 0.50 0.4pmol/µl 
dH2O n/a 15.15 n/a 
Total volume n/a 20.00 n/a 
*deoxynucleoside triphosphate; n/a: not applicable 
 
 
The master-mix was distributed in volumes of 20µl in 0.2ml PCR tubes to which five µl of DNA 
extract was added. The thermocycling parameters given in Table 3.7 were used for the PCR 
reaction. 
 
Table 3. 7 Cycling parameters for pre-nested PCR of pol/surface region 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 5 minutes 
Denaturation 
34 cycles 
94°C 30 seconds 
Annealing 55°C 30 seconds 
Extension 72°C 1 minute 
Final Extension 1 hold 72°C 2 minutes 
 
 
Nested PCR 
 
A second round of PCR amplification was performed on the pre-nested samples to increase the 
specificity of the reaction and to increase the product yield. The primers used are shown in Table 
3.8 and the master mix was prepared using the reagents listed in Table 3.9. 
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Table 3. 8 Primers used for nested PCR of pol/surface region 
Name Sequence 
Binding position 
from Eco R1 site 
HBV P_Forward
   
5′- TCA TCC TCA GGC CAT GCA GT -3′ 3247 – 3266 
HBV M_Reverse 5′- GAC ACA CTT TCC AAT CAA TNG G -3′ 997 – 976 
 
 
 
Table 3. 9 Master mix for nested PCR of pol/surface region 
Reagents 
Starting 
Concentration 
Volume/µl 
x1 
Final 
Concentration 
PCR Buffer 10x 5.0 1x 
MgCl2 50mM 1.5 1.5mM 
dNTPS 10mM 1.0 0.2mM 
Taq 
Polymerase 
 0.2  
HBV 3 20pmol/µl 1.0 0.4pmol/µl 
HBV Z 20pmol/µl 1.0 0.4pmol/µl 
dH2O n/a 39.3 n/a 
Total volume n/a 49.0 n/a 
pmol/µl: picomole per microliter; n/a: not applicable 
 
The master-mix was aliquoted in volumes of 49µl into 0.2ml PCR tubes to which one µl of the 
pre-nested product was added. The cycling parameters given in Table 3.10 were used for the 
nested PCR reaction. 
 
Table 3. 10 Cycling parameters for nested PCR of pol/surface region 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 5 minutes 
Denaturation 
34 cycles 
94°C 30 seconds 
Annealing 50°C 30 seconds 
Extension 72°C 1 minute 
Final Extension 1 hold 72°C 7 minutes 
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Gel electrophoresis and visualization 
 
A 1.8% agarose gel was prepared by melting 1.8 grams of agarose powder (SeaKem® LE 
Agarose, LONZA, Rockland, ME, USA) in 100ml of 1x Tris Acetate Buffer. Novel Juice 
(GeneDireX, Taiwan), a non-mutagenic fluorescent dye supplied in a 6x loading buffer was used 
to visualize the DNA bands. One microlitre of Novel Juice was mixed with five microlitres of 
each nested PCR product before the mixture was loaded into separate wells on the gel. The 
samples were separated alongside a 1kb DNA ladder (GeneRuler™ 1 kb DNA Ladder, 
Fermentas, ThermoFisher Scientific, USA) for at least 30 minutes at 60 volts. The gel was then 
viewed under ultraviolet light using the Platinum HD Gel Documentation System (UVItec 
Limited, Cambridge, UK) and the image acquired using the UVIband-1D gel analysis software. 
The expected product size was around 1kb. Samples which were judged to have enough 
amplified DNA to be sequenced (based on the visibility of crisp single bands of the correct size) 
were then selected for downstream processing. 
 
Clean-up and analysis of PCR product 
 
The PCR products were purified using the QIAGEN® QIAquick PCR Purification Kit by 
following manufacturer’s instructions. 
 
The purified DNA was analysed spectrophotometrically using the NanoDrop® ND-100 (Thermo 
Fisher Scientific, USA). The concentration and purity of the nucleic acid was automatically 
calculated with the “Nucleic Acid” Application module of the NanoDrop Software Version 
3.1.0. If the purified DNA product had a concentration above 20ng/µl, it was diluted until it was 
within the required range (5-20ng/µl) for the sequencing PCR reaction. 
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Sequencing PCR reaction 
 
The sequencing PCR reaction was carried out in a 96-well plate using four different primers to 
sequence the region of interest. These primers (Table 3.11) were diluted to 2pmol/µl before 
being used. A master mix consisting of the ready-to-use reagents shown in Table 3.12 was 
prepared and distributed in volumes of 8µl into the appropriate number of wells. Next, 1µl of 
each primer and 1µl of purified template DNA from each sample was added to the appropriate 
wells. The cycling conditions shown in Table 3.13 were used. 
 
Table 3. 11 Sequencing primers targeting the pol/surface region 
Name Sequence 
Binding 
position from 
Eco R1 site 
HBV P_Forward 5′- TCA TCC TCA GGC CAT GCA GT -3′ 3247 – 3266 
HBV M_Reverse 5′- GAC ACA CTT TCC AAT CAA TNG G -3′ 997 – 976 
HBV H Forward 5′-TAT CAA GGA ATT CTG CCC GTT TGT CCT -3′ 628 – 655 
HBV N Reverse 5′-ACT GAG CCA GGA GAA ACG GAC TGA GGC -3′ 682 – 656 
 
 
Table 3. 12 Master mix for sequencing reaction of pol/surface region 
 
 
 
 
 
 
 
 
Table 3. 13 Cycling parameters for sequencing reaction of pol/surface region 
Cycling parameter Cycles Temperature Time 
Denaturation 
30 cycles 
96°C 20 seconds 
Annealing 50°C 20 seconds 
Extension 60°C 4 minutes 
 
Reagents 
Volume/µl 
x1 
Terminator ready reaction mix 1 
ABI sequencing buffer 3 
Water 4 
Total volume 8 
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Sequencing clean-up 
 
The sequencing PCR reactions were cleaned up using the BigDye® Xterminator Purification Kit 
(Applied Biosystems, Foster City, California, USA) consisting of SAM™ and XTerminator® 
solutions. These two reagents were brought to room temperature and vortexed for ten seconds at 
maximum speed before use. 
 
The sequencing 96-well plate was centrifuged for one minute at 1000 RCF in a swing-bucket 
centrifuge. Next, 45µl of SAM solution and 10µl of Xterminator
®
 solution were added to each 
well before the wells were sealed with a clear, adhesive film. The 96-well plate was then 
vortexed for 30 minutes at 2000 RCF and centrifuged for one minute at 1000 RCF. 
 
Sequence Analysis 
 
Capillary electrophoresis was performed on the samples using the ABI Prism 3130XL Genetic 
Analyzer (Applied Biosystems, Foster City, California, USA). The information obtained was 
converted to raw data files using DNA sequencing analysis software from Applied Biosystems, 
(USA). The length of the capillaries allowed sequence reads of around 600 base pairs (bp) to be 
obtained. 
 
The raw trace files were further analysed using Sequencher 4.8 (Gene Codes Corporation, 
Michigan, USA). The quality of each sequence was improved individually by looking at the 
chromatograms and trimming the ends where necessary. The four sequences for each patient 
were then aligned to create a consensus sequence. Mismatches or ambiguities were rectified 
manually. The consensus sequence was renamed and saved in FASTA format before being 
blasted against the Stanford University HBVSeq sequence database. 
(http://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html).  
 
This allowed the genotype identification of the HBV strains and the detection of any clinically-
relevant mutations in the sequences. 
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3.5.4 WHOLE GENOME SEQUENCING OF HBV DNA POSITIVE SAMPLES 
Whole genome sequencing was attempted on samples which were HBV DNA positive. Only 
samples which had more than 10
8
 IU/ml of viral DNA could be sequenced. Firstly, the whole 
genome was first amplified in two separate reactions resulting in two large fragments which were 
then sequenced.  
 
Both PCR reactions used MyFi™ Mix from Bioline (Bioline, GmbH, Germany) which utilizes a 
high-fidelity DNA polymerase and requires only the addition of specific primers and template 
for amplification. 
 
Two sets of primers were selected to amplify a fragment of around ~2.5kb and a smaller 
fragment of ~1.2kb respectively. The reactions were prepared using the reagents listed in Table 
3.14 and Table 3.15 and the thermocycling parameters are given in Table 3.16. 
 
Table 3. 14 Master mix for PCR of 2.5kb fragment of HBV genome 
Reagents 
Starting 
Concentration 
Volume/µl 
x1 
Final 
Concentration 
MyFi Mix 2x 25 1x 
UBC7_Forward 20pmol/µl 1 0.4pmol/µl 
UBC6_Reverse 20pmol/µl 1 0.4pmol/µl 
dH2O n/a 18 n/a 
Total volume n/a 45 n/a 
n/a: not applicable 
 
 
Table 3. 15 Master mix for PCR of 1.2kb fragment of HBV genome 
Reagents 
Starting 
Concentration 
Volume/µl 
x1 
Final 
Concentration 
MyFi Mix 2x 25 1x 
H4072_Forward 20pmol/µl 1 0.4pmol/µl 
91DMas_Reverse 20pmol/µl 1 0.4pmol/µl 
dH2O n/a 18 n/a 
Total volume n/a 45 n/a 
n/a: not applicable 
 
  
Stellenbosch University http://scholar.sun.ac.za
 71 
 
Table 3. 16 Cycling parameters for PCR of two fragments of HBV genome 
Cycling parameter Cycles Temperature Time 
Initial denaturation 1 hold 95°C 3 minutes 
Denaturation 
15 cycles 
94°C 25 seconds 
Annealing 50°C 30 seconds 
Elongation 68°C 3.5 minutes +30s/5cycles 
Denaturation 
25 cycles 
94°C 25 seconds 
Annealing 60°C 30 seconds 
Elongation 68°C 5 minutes +9s/cycle 
Final Elongation 1 hold 68°C 7 minutes 
 
 
The two PCR products were then purified as described previously, and a sequencing reaction 
plate was set up using the master mix given in Table 3.12. 
 
Sequencing of the 2.5kb fragment was executed using a set of nine different primers (given in 
Table 3.17). Another set of five primers (given in Table 3.18) were used to amplify different 
overlapping sections of the 1.2kb fragment. The combination of these primers and fragments 
allowed for the sequencing of the entire 3.2kb genome of HBV. 
 
The thermocycling conditions given in Table 3.13 were used on all the primers for the 
sequencing reaction except for the 0.7F_New primer reaction. This primer had a melting 
temperature of 37°C and therefore in the sequencing PCR an annealing temperature of 37°C was 
used for 20 seconds. 
 
The sequencing reaction products were cleaned as previously described before being subjected to 
capillary electrophoresis using the ABI Prism 3130XL Genetic Analyzer (Applied Biosystems, 
Foster City, California, USA) and the sequences were analysed using DNA sequencing analysis 
software from Applied Biosystems (USA). 
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Table 3. 17 Sequencing primers targeting the 2.5kb fragment 
Name Sequence 
Binding position 
from Eco R1 site 
HBV Z_Forward* 5′- AGC CCT CAG GCT CAG GGC ATA -3′ 3134 – 3154 
HBV 3_Reverse* 5′- CGT TGC CKD GCA ACS GGG TAA AGG -3′ 1170 – 1146 
HBV H_Forward* 5′- TATCAAGGAATTCTGCCCGTTTGTCCT -3′ 628 – 655 
HBV P_Forward* 5′- TCA TCC TCA GGC CAT GCA GT -3′ 3247 – 3266 
UBC7_Forward
#
 5′- CTT TTT CAC CTC TGC CTA RTC A -3′ 1828 – 1850 
UBC6_Reverse
#
 5′- AAA AAG TTR CAT GRT GMT GG -3′ 1813 – 1832 
0.7F_New_Forward
#
 5′- GCT AGR TTY TAT CC -3′ 2694 – 2707 
B2as_Reverse
$
 5′- GGCAGCACASCCGAGCAGCCATGG -3′ 1402 – 1379 
0.7R_Reverse
#
 5′- CAATTTATGCCTACAGCCTCC -3′ 1803 – 1783 
# Primer sequences were obtained from Samreen Ijaz, HPA (personal communication); * Primer sequences were obtained from 
the HPA website: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684; $ Primer sequence was obtained from 
Guillaume Fallot, INSERM (personal communication) 
 
 
Table 3. 18 Sequencing primers targeting the 1.5kb fragment 
Name Sequence 
Binding position 
from Eco R1 site 
CSeqQR_Reverse
#
 5′- TCT TGC CCA AGG TCT TAC AT -3′ 1747 – 1766 
Core_RT_Forward* 5′- CCT GGG TGG GAA GTA ATT TGG -3′  
91DMas_Reverse
$
 5′- CCC AAG AAT ATG GTG ACC C -3′ 3028 – 3010 
UBC6_Reverse
#
 5′- CTT TTT CAC CTC TGC CTA RTC A -3′ 1932 – 1954 
0.7new_Forward
#
 5′- GCT AGR TTY TAT CC -3′ 2698 – 2712 
# Primer sequences were obtained from Samreen Ijaz, HPA (personal communication); $ Primer sequence was obtained from 
Guillaume Fallot, INSERM (personal communication); * Primer sequence was obtained from Qian et al. (2005) 
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3.5.5 PHYLOGENETIC ANALYSIS OF SEQUENCES OBTAINED FROM 
SEQUENCING OF POL/SURFACE REGION AND WHOLE GENOME 
Phylogenetic trees comparing sequences obtained in sections 3.5.3 and 3.5.4 to each other and to 
reference sequences of HBV genotype A from South Africa (downloaded from GenBank) were 
constructed in MEGA5 (Tamura et al. 2011). These reference sequences were obtained from 
online searches on GenBank and from Maponga TG, MSc Thesis, Stellenbosch University 
(2012). 
 
For the phylogenetic analysis, the evolutionary history was inferred using the Neighbor-Joining 
method (Saitou and Nei, 1987) and the evolutionary distances were calculated using the Kimura 
2-parameter method (Kimura 1980). The Neighbour-Joining method was used as it is able to 
process large volumes of data quickly. The Kimura 2-parameter generates evolutionary distance 
between sequences and is able to differentiate between base transitions and transversions.  
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3.5.6 QUALITY CONTROL FOR MOLECULAR ASSAYS 
DNA Extraction 
 
The DNA extractions were performed in a laminar flow cabinet to minimize the risk of 
contamination. The microcentrifuge tubes containing the samples were briefly centrifuged before 
being opened, to eliminate the risk of aerosol formation from any droplets on the inside of the 
tube caps. During the extraction process, gloves were changed when dealing with sterile 
consumables. Reagents were aliquoted into 50ml conical centrifuge tubes before being used so 
that the stock solutions were not exposed to a possible source of contamination by repeated 
pipetting from the original bottles containing the reagents. With each extraction batch, NHP was 
used as a negative control to ensure that there was no crossover contamination either from the 
reagents used or from the operator. A positive control was not included in the extraction process 
as an internal control was added to every sample including the negative control. In the 
subsequent real time PCR which was performed on the extracted samples, the detection of the 
internal control in all the extracts ensured that the extraction process was working. 
 
PCR 
 
Reagent preparation and amplicon addition for the PCR was done in separate rooms to prevent 
contamination. The master mix was prepared in a room designated as a ‘clean area’ which is 
exclusively used for the preparation of master mixes. Before setting up a reaction, the bench top 
and the micropipettes were wiped, first with 0.35% bleach and then with 70% ethanol. DNA 
addition was done in a separate room and the thermocyclers were housed in a room designated as 
a ‘dirty area’. Under no circumstances was the operator allowed to move from a ‘dirty area’ into 
a ‘clean area’. 
 
The different reagents were thawed on ice to prevent degradation. Primers and probes were 
aliquoted into volumes of five and three microlitres respectively to prevent degradation through 
several freeze-thaw events. The DNA extracts were allowed to thaw at 4°C while the master mix 
was prepared. 
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Conventional PCR 
 
An appropriate positive control was included with each conventional PCR and sequencing 
reaction to ensure the validity of the results. A negative control consisting of the master mix and 
nuclease-free water was included with each PCR run. This ensured that the reagents were not 
contaminated and would not cause the detection of false positives. 
 
Real-time PCR 
 
The standards used in the real-time PCR were run in duplicate to reduce error and to increase the 
confidence in the interpreted results. No positive control was included in the runs as the 
amplification of the internal control in every individual tube was judged to be sufficient to ensure 
that amplification conditions were optimal. A no template control consisting of the master mix 
and nuclease-free water was included with each real-time PCR run. This ensured that the 
reagents were not contaminated and would not cause the detection of false positives. To ensure 
that consistency between each separate run, a sample of known viral load, termed the working 
control, was included with each real-time PCR run. 
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CHAPTER FOUR: RESULTS 
 
4.1 SAMPLE AND DATA COLLECTION 
A total of 1468 samples were received by the NHLS, Division of Medical Virology, Tygerberg 
Hospital between the 8
th
 of June 2011 and the 18
th
 of August 2011. From these, 604 samples 
with more than 100µl residual plasma were selected for the current study. An additional 396 
samples were selected from a total of 1114 samples received from the 6
th
 of October 2011 to the 
13
th
 of February 2012. The study population made up 39% of the sample population. 
The demographics of the tested population are summarised in Table 4.1 below. 
 
Table 4. 1 Demographics of study population 
Characteristic 
Total sample population
*
 
(n=2582) 
Study population 
(n=1000) 
Age   
Median (range), days 45 (0-730) 46 (0-540) 
Sex   
Male, % 41.2 48.7 
Unknown gender, % 15.7 2.9 
HIV status   
HIV-infected, % 4.6 6.1 
* Total number of samples received for HIV-1 PCR testing by the NHLS during the sample collection period 
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Vaccine related HBsAg  
= 7 – BU1 to BU7 
Total HBV infection: 4 
1. 3 HBsAg and HBV DNA – BH1 to BH3 
2. 1 HBV DNA alone – BH4 
Total number of samples received 
N = 2582 
Total number tested  
= 1000 
1582 excluded: 
1. Sample volume < 100µl 
2. Inconclusive HIV result 
3. Patient not resident of Western 
Cape Province 
4. Child older than 18 months 
Total HBsAg positive  
= 10 
DNA positive  
= 4 
Figure 4. 1 Categorisation of samples at screening 
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4.2 FOLLOW-UP OF HBsAg AND/OR DNA POSITIVE PATIENTS 
From the screening tests described elsewhere (section 4.3.1 and 4.4.3), 11 samples were found to 
be HBsAg and/or HBV DNA positive. Using each positive sample’s code, the name of the 
corresponding infant was retrieved from a digital database and the mother of the infant was 
contacted through their clinic. Ten of eleven infants and 11/11 mothers were successfully traced. 
Where the term ‘patients’ is used henceforth, it encompasses both tested infants and mothers. 
 
One infant had been sent back to his hometown and was lost to follow-up. Insufficient blood was 
received from another infant who could then only be tested for HBsAg and HBV DNA at follow-
up. Although a request was made to re-bleed this infant, by the time of submission, no blood 
sample had been received for further testing. The demographics of the followed-up infants and 
their mothers are shown in Table 4.2. 
 
Table 4. 2 Demographics of the followed up infants and their mothers 
Characteristic Infants (n=10) Mothers (n=11) 
Age   
Median at screening (range), days 45 (41-120) - 
Median at follow up (range) 227.5 days (143-327 days) 35 years (24-43 yrs) 
Sex   
Male, % 90 - 
HIV status   
HIV-infected, % 0 100 
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SEROLOGY RESULTS 
4.3.1 PREVALENCE OF HBsAg AT SCREENING STAGE 
Out of the 1000 infants screened using the Murex HBsAg Version 3 kit, 11 were found to be 
reactive for HBsAg. An HBsAg neutralization test was performed on these 11 HBsAg-positive 
samples. Following neutralization, one sample was found to be negative. Of the remaining ten 
samples, eight were confirmed to be true HBsAg positives as a reduction of at least 50% was 
observed in the OD between antiHBs positive and negative wells. 
 
One sample displayed an OD which was above the linear detection range (0–3.3) of the 
spectrophotometer in both wells (with and without antiHBs). This was attributed to a very high 
level of HBsAg in the patient’s plasma. Another sample had insufficient plasma for the 
neutralization test and was thus diluted 1:8 in NHP. Although a substantial reduction in OD 
between antiHBs positive and negative wells was observed for this sample (0.090 to 0.052), the 
absorbance from the antiHBs-negative well was below the threshold of positivity (0.102). The 
low OD seen in the antiHBs-positive well was attributed to the high dilution factor and the 
sample was therefore considered to be HBsAg positive. This patient was subsequently shown to 
be HBV uninfected.  
These results are summarised in Table 4.3 below. 
 
 
Table 4. 3 HBsAg screening and confirmation results 
Samples initially positive for HBsAg 11/1000 (1.1%) 
Samples confirmed positive for HBsAg by neutralization 10/1000 (1.0%) 
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The detailed results observed for the neutralization test are shown in Table 4.4. 
Table 4. 4 Absorbance values for screening HBsAg neutralization test 
Patient 
Number 
Absorbance / 
NHP Well 
Absorbance / 
AntiHBs Well 
Cut-Off 
% Reduction in 
Absorbance 
1 0.332 0.052 0.102 84 
2 0.090
#
 0.052
#
 0.102 42 
3 > 3.300* > 3.300* 0.102 N/A 
4 0.151 0.062 0.102 59 
5 0.154 0.059 0.101 62 
6 0.879 0.057 0.101 94 
7 0.122 0.041 0.101 66 
8 0.045 0.052 0.101 NEG 
9 0.270 0.046 0.101 83 
10 0.139 0.049 0.101 65 
11 0.319 0.071 0.101 78 
%: Percentage; #absorbance value in NHP just below cut-off, dilution of 1:8 done on this sample; * Absorbance value  
out of range; absorbance values too high for neutralization to be possible without further dilution; N/A not applicable; 
NEG: Negative 
 
 
4.3.2 PREVALENCE OF HBsAg AT FOLLOW-UP 
 
The follow-up data of the 11 infants included the dates on which they had received their 
vaccinations against HBV. It was confirmed that the blood sample for the HIV-1 test had been 
taken from these infants on the same day or very close to the date they had received one of three 
doses of the HB vaccine. The infants and their mothers were therefore divided into two groups. 
One group encompassed the four HBV DNA-positive infants and their mothers and was termed 
the ‘infected group’. These infants and their mothers were code-named BH1 to BH4 and MH1 to 
MH4 respectively. The other group was made up of the seven infants who were positive for 
HBsAg alone and their mothers and was termed the ‘uninfected group’. They were code-named 
BU1 to BU7 and MU1 to MU7 respectively. 
 
Additional information on the mothers from the infected group was available and it was seen that 
these four mothers had CD4 counts above 350 cells/mm
3
 and that they were therefore not on 
ART. 
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The followed-up patients were first tested for HBsAg. After testing, 66.7% (2/3) of infants (BH1 
to BH3) and 100% (4/4) of mothers (MH1 to MH4) belonging to the infected group were found 
to be positive for HBsAg. None of the tested infants (7/7) and mothers (7/7) from the uninfected 
group was positive for HBsAg on follow-up. 
 
These six HBsAg positive patients were further tested by the HBsAg neutralization assay. Two 
out of two infants and all four mothers were confirmed to be HBsAg positive on neutralisation. 
The absorbance values observed upon neutralization are shown in Table 4.5. 
 
Table 4. 5 Absorbance values for HBsAg neutralization test of infected group at follow-up 
Patient 
Absorbance/ 
NHP Well 
Absorbance/ 
AntiHBs Well 
% reduction in 
absorbance 
MH1 >3.300 0.122 >50 
BH2 NT NT NT 
MH2 0.814 0.071 91 
BH2 >3.300 0.093 >50 
MH3 2.179 0.044 98 
BH3 0.525 0.060 89 
MH4 >3.300 0.052 >50 
BH4* ND ND ND 
* Patient was lost to follow-up; %: Percentage; BH: infant from infected group; MH: mother from infected group; NT: Not tested 
as was HBsAg negative; ND: Not Done 
 
 
4.3.3 PREVALENCE OF HBeAg AND AntiHBe IN HBsAg POSITIVE SAMPLES  
 
In the infected group, two HBsAg positive infants and the four HBsAg positive mothers were 
tested and were all positive for HBeAg. The absorbance values observed in these infants and 
mothers were higher than the detection limit of the spectrophotometer except for MH2. 
The six HBeAg-positive patients were also tested for antiHBe. The two tested infants were 
negative for antiHBe. Out of the four tested mothers, only MH2 was positive for antiHBe. 
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4.3.4 PREVALENCE OF AntiHBc IN ALL FOLLOWED-UP SAMPLES 
 
The followed up patients with sufficient plasma (9/10 infants and 11/11 mothers) were tested for 
antiHBc. In the infected group, two (BH2 and BH3) out of three tested infants and all four tested 
mothers were positive for antiHBc. In the uninfected group, none of the tested infants (0/6) and 
three out of seven mothers were positive for antiHBc. 
 
A summary of the serological results of the infants and mothers from the infected and uninfected 
groups at screening and follow-up are shown in Table 4.6 and Table 4.7 respectively. 
 
Table 4. 6 Serological results of mother-child pairs in infected group at follow-up 
PATIENT HBsAg HBeAg AntiHBc AntiHBe 
MH1 + + + − 
BH1 − − − ND 
MH2 + + + + 
BH2 + + + − 
MH3 + + + − 
BH3 + + + − 
MH4 + + + − 
BH4* ND ND ND ND 
* Patient was lost to follow-up; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen;  
AntiHBc: antibody to hepatitis B core antigen; AntiHBe: antibody to hepatitis B e antigen;  
BH: Infant from infected group; MH: Mother from infected group; − : Negative; + : Positive; ND: Not done  
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 Table 4. 7 Serological results of mother-child pairs in  
uninfected group at follow-up 
PATIENT HBsAg AntiHBc 
MU1 − + 
BU1 − − 
MU2 − + 
BU2 − − 
MU3 − − 
BU3 − − 
MU4 − + 
BU4 − NT
#
 
MU5 − − 
BU5 − − 
MU6 − − 
BU6 − − 
MU7 − − 
BU7 − − 
HBsAg: hepatitis B surface antigen; AntiHBc: antibody to hepatitis B core antigen;  
BU: Infant from uninfected group; MU: Mother from uninfected group; − : Negative;  
+ : Positive; NT# Not tested because of insufficient sample volume   
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4.3.5 PREVALENCE OF AntiHBs IN HBsAg NEGATIVE SAMPLES 
Infants who were negative for HBsAg were tested for antiHBs. However, due to the small 
volume of plasma, only one out of seven infants from the uninfected group could be tested for 
this marker. The only HBsAg negative infant from the infected group was also tested for 
antiHBs. These two infants were found to have protective levels of antiHBs (greater than 10 
IU/L). 
MU7, who was positive for antiHBe, was tested for antiHBs and was found to have levels of 
antiHBs of greater than 10 IU/L. 
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4.3 MOLECULAR TESTING 
 
4.4.1 VALIDATION OF POOLING ASSAY 
The validation test results (Table 4.8) showed that the lowest detectable viral load using the real-
time PCR assay was at the dilution of 1:20 for the sample with 250 IU/ml and at the dilution of 
1:10 for the sample with 100 IU/ml. The 1:20 dilution of the 250 IU/ml working solution gave a 
final viral load of 12.5 IU/ml while the 1:10 dilution of the 100 IU/ml working solution gave a 
final viral load of 10 IU/ml. The higher value was chosen as the detection limit and therefore DL 
was determined to be 12.5 IU/ml. Since four samples were pooled, the limit of detection of the 
pooled assay, PL, was calculated to be 50 IU/ml. A working solution containing 50 IU/ml was 
prepared and one-fold dilutions were run in duplicate on three different days. The results 
obtained (Table 4.8) confirmed that PL was 50 IU/ml. 
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Table 4. 8 Validation results of pooling assay. Samples were tested in duplicate on three 
different days 
Stock 
solution 
Working 
solution 
Ct1 VL1 Ct2 VL2 Ct3 VL3 
250 IU/ml 
Neat 34.99 323 39.53 65 ND ND 
Neat 44.5 1 38.79 108 35.03 300 
 
1:2 36.22 147 39.81 54 39.73 9 
 
1:2 35.39 250 38.11 170 36.15 131 
 
1:3 41.91 4 40.62 32 35.56 202 
 
1:3 40.83 8 40.63 31 36.9 75 
 
1:4 40.03 13 39.24 80 39.77 9 
 
1:4 37.11 83 40.54 33 37.16 62 
 
1:5 42.14 3 39.69 59 38.45 24 
 
1:5 38.29 39 39.35 74 38.57 22 
 
1:6 37.72 56 40.57 33 36.6 94 
 
1:6 39.95 14 42.05 12 38.25 28 
 
1:8 ND ND 40.44 36 38.16 29 
 
1:8 40.92 7 42.81 7 38.82 18 
 
1:10 38.2 41 41.4 19 40.97 4 
 
1:10 39.28 21 38.8 107 38.65 20 
 
1:20 ND ND 40.9 26 40.29 6 
 
1:20 39.65 16 40.91 26 39.27 13 
 
1:25 39.22 22 ND ND ND ND 
 
1:25 41.19 6 ND ND ND ND 
        
100 IU/ml 
Neat 35.77 197 37.27 104 37.54 59 
Neat 35.87 183 35.74 278 36.93 88 
 
1:2 38.82 25 38.73 41 38 43 
 
1:2 36.09 158 37.94 68 37.68 54 
 
1:3 38.04 42 40.01 18 40.01 11 
 
1:3 ND ND ND ND 41.28 5 
 
1:4 38.87 24 ND ND 40 11 
 
1:4 37.73 52 38.94 36 40.39 9 
 
1:5 38.1 41 38.87 37 39.61 15 
 
1:5 38.51 31 39.57 24 37.75 51 
 
1:6 38.86 24 38.78 40 ND ND 
 
1:6 37.74 52 ND ND 41.81 3 
 
1:8 39.5 16 38.21 57 43.58 1 
 
1:8 39.25 19 39.98 18 ND ND 
 
1:10 39.64 14 38.15 59 ND ND 
 
1:10 37.29 70 39.33 28 40.7 7 
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Stock 
solution 
Working 
solution 
Ct1 VL1 Ct2 VL2 Ct3 VL3 
50 IU/ml 
Neat 38.65 42 34.55 97 38.34 34 
Neat 36.99 125 35.09 68 41.32 5 
 
1:2 39.63 22 32.81 294 38.43 32 
 
1:2 38.25 54 37.66 13 ND ND 
 
1:3 37.23 107 37.3 17 40.61 8 
 
1:3 38.01 64 37.69 13 ND ND 
 
1:4 37.69 78 ND ND 40.21 10 
 
1:4 38.94 34 34.87 79 ND ND 
 
1:5 39.81 19 ND ND 40.53 8 
 
1:5 38.92 35 ND ND ND ND 
 
1:6 39.67 21 ND ND 39.38 17 
 
1:6 38.14 58 37.38 16 ND ND 
Ct: Cycle at which the fluorescence observed in the sample crossed the detection threshold; VL: Viral load; ND: Not Detected 
 
 
4.4.2 INDIVIDUAL AND POOLED VIRAL DNA EXTRACTIONS 
 
Out of the 1000 samples screened for HBsAg, 989 were serologically negative and therefore not 
further tested by the neutralization assay. DNA was only extracted from the first 600 
serologically negative samples and the 11 samples which were tested by neutralization.  
Of the 600 samples, 228 had less than 150µl of plasma available and were extracted individually. 
The remaining 372 HBsAg negative samples, which had more than 150µl of plasma available, 
were pooled and extracted in 93 batches of four each. Individual DNA extractions were also 
done on the 11 samples which were tested using the HBsAg neutralization assay.  
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4.4.3 VIRAL LOAD TESTING AT SCREENING STAGE 
 
The 611/1000 extracted samples were tested for the presence of HBV DNA by real-time PCR. 
None of the 372 pooled and none of the 228 individually-extracted HBsAg negative samples had 
a detectable viral load. 
 
Of the ten confirmed HBsAg positive samples, three were positive for HBV DNA. Two samples 
had viral loads of 10
2
 IU/ml and 5 x 10
4
 IU/ml respectively. The third sample which had 
previously shown OD values greater than the detection range of the spectrophotometer for the 
HBsAg neutralization test, had a viral load of >10
8
 IU/ml. One sample which was HBsAg 
negative was HBV DNA-positive with a low viral load of 5 x 10
1
 IU/ml. These four samples 
made up the infected group. 
 
The remaining HBsAg positive samples were negative for HBV DNA and were categorized as 
the uninfected group. 
 
Based on the HBsAg and HBV DNA results, the prevalence of HBV infection in this cohort of 
1000 infants was calculated to be 0.4% (4/1000). 
 
4.4.4 VIRAL LOAD TESTING AT FOLLOW-UP 
In the infected group, a positive viral load was detected in 2/3 followed-up infants and 4/4 
mothers. The two infants (BH2 and BH3) had a HBV viral load of greater than 10
8
 IU/ml. Their 
mothers (MH2 and MH3) had a viral load of 10
3 
IU/ml and 10
8
 IU/ml respectively. The other 
two mothers MH1 and MH4 had viral loads of greater than 10
8
 IU/ml. 
 
In the uninfected group, none of the tested infants (0/7) and mothers (0/7) was positive for HBV 
DNA. 
A summary of the serological and viral load results obtained for the infected group at screening 
and follow-up is given in Table 4.9. 
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      Table 4. 9 Serological and molecular results of mother-child pairs in infected group at screening and at follow-up 
 
SCREENING  FOLLOW-UP 
PATIENT  HBsAg 
HBV DNA 
IU/ml 
HBsAg AntiHBe HBeAg AntiHBc 
HBV DNA 
IU/ml 
MH1  ND ND + − + + 1 x 10
8
 
BH1  + 1 x 10
2
 − ND ND − − 
MH2  ND ND + + + + 1 x 10
3
 
BH2  + 2 x 10
8
 + − + + 6 x 108 
MH3  ND ND + − + + 4 x 10
8
 
BH3  + 5 x 10
4
 + − + + 2 x 109 
MH4  ND ND + − + + 4 x 10
7
 
BH4*  − 5 x 10
1
 ND ND ND + ND 
 *Patient was lost to follow-up; IU/ml: International Units per millilitre; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; AntiHBe: antibody to 
hepatitis B e antigen; AntiHBc: antibody to hepatitis B core antigen; BH: Infant from infected group; MH: Mother from infected group; − : Negative; + : Positive; 
ND: Not done  
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4.4.5 SEQUENCING OF POL/SURFACE REGION RESULTS 
The pol/surface gene of the HBV strains was sequenced in the samples from the two infants and 
four mothers who were positive for HBV DNA. A typical nested PCR yielded bands as shown in 
Figure 4.2. 
 
 
Figure 4. 2 Gel of typical bands obtained in 3/6 patients after nested PCR of pol/surface 
region M: 1kb Molecular Weight marker; N: No-template control 
 
After the clean-up step, the products were analysed spectrophotometrically. The concentration 
and the purity of the DNA obtained by readings at A260nm and A260/280nm respectively are shown 
in Table 4.10.  
 
Table 4. 10 Concentration and Purity of DNA after clean-up 
Sample ID ng/µl A260/280nm 
MH1 21.50 2.29 
MH2 19.92 1.97 
BH2 16.20 2.10 
MH3 63.45 1.93 
BH3 59.72 1.86 
MH4 59.71 1.84 
M M 
1000 bp 
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The DNA from BH3, MH3 and MH4 was diluted since it was higher than the recommended 
range (5-20ng/µl) for the sequencing PCR reaction. The samples from these patients were diluted 
with buffer EB from the QIAquick purification kit so that 1µl of each sample could be used for 
the sequencing reaction. 
 
After the sequences were analysed, the ends were trimmed and the sequences amplified by the 
four different primers. The sequences were then aligned, a contiguous sequence was obtained 
which was approximately 900 bp long for all six patients. 
 
Analysis on the HepSeq website of the sequences of the two infants and the four mothers showed 
they belonged to genotype A. No mutation associated with drug-resistance or vaccine-escape 
was identified in the pol/surface region of HBV strains in these patients. 
 
The sequences from the mother-child pairs were used to construct a phylogenetic tree (figure 
4.3). The HBV strains from the two mother-child pairs (MH2/BH2 and MH3/BH3) were found 
to be identical. 
 
A separate tree was drawn to compare the four maternal sequences with other South African 
HBV strains (Figure 4.4).  
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Figure 4. 3 Phylogenetic tree of mother-child pairs with HBV strains belonging to 
subgenotype A1 based on pol/surface region 
BH: infant from infected group; MH: mother from infected group; Sequences D002438, 
D001801, D002911 and D002784 were sequenced from patients from the Western Cape 
(Maponga TG, MSc Thesis, Stellenbosch University, 2012). Sequences with accession numbers 
AY233279.1, AY233287.1, AY903452.1, AY233280.1, Z72478.1 and GQ184326.1 were 
downloaded from GenBank. 
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei 1987). 
The optimal tree with the sum of branch length = 0.16052268 is shown. The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. The evolutionary distances were computed using the Kimura 2-parameter 
method (Kimura 1980) and are in the units of the number of base substitutions per site. The 
analysis involved 14 nucleotide sequences. There were a total of 917 positions in the final 
dataset. Evolutionary analyses were conducted in MEGA5 (Tamura et al. 2011).  
 MH2
 BH2
 D002784
 D002911
 AY903452.1 SA A1
 D003920
 AY233279.1 SA A
 AY233287.1 SA A
 D001801
 D002438
 BH3
 MH3
 GQ184326.1 SA C1
0.01
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Figure 4. 4 Phylogenetic tree comparing maternal HBV strains to South African sequences 
MH: mother from infected group; Sequences D001801, D002911 and D002784 were sequenced 
from patients from the Western Cape (Maponga TG, MSc Thesis, Stellenbosch University, 
2012). Sequences with accession numbers AY233279.1, AY233287.1, AY903452.1 and 
GQ184326.1 were downloaded from GenBank. All sequences belong to subgenotype A1 except 
for GQ184326.1 which belongs to genotype C. 
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei 1987). 
The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. The evolutionary distances were computed using 
the Kimura 2-parameter method (Kimura 1980) and are in the units of the number of base 
substitutions per site. The analysis involved 14 nucleotide sequences. There were a total of 917 
positions in the final dataset. Evolutionary analyses were conducted in MEGA5 (Tamura et al. 
2011).  
 MH4
 D002784
 MH2
 AY903452.1 SA A1
 MH1
 D002911
 AY233279.1 SA A
 AY233287.1 SA A
 MH3
 D001801
 GQ184326.1 SA C1
0.01
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4.4.6 WHOLE GENOME SEQUENCING RESULTS 
In the infected group, the whole genome in 5/6 samples could be sequenced. The viral load from 
MH2 was too low for whole genome sequencing using the assay described in section 3.5.4. 
A gel with typical bands obtained with the PCR on the two fragments for each sample is shown 
in figure 4.6. 
 
 
Figure 4. 5 Typical bands (1.2 and 2.5 kb) obtained with PCR for whole-genome 
sequencing 
 
After the clean-up step, the products were analysed spectrophotometrically. The concentration 
and the purity of the DNA obtained by readings at A260nm and A260/280nm respectively for both 
fragments are shown in Table 4.10 and Table 4.11. 
 
 
 
 
 
1000  
bp 
1500 
 bp 
2500 bp 
3000 bp 
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Table 4. 11 Concentration and Purity of DNA after clean-up of 2.5kb fragment 
Sample ID ng/µl A260/280nm 
MH1 33.86 2.1 
BH2 59.08 1.87 
MH3 25.93 2.14 
BH3 61.5 2.1 
MH4 43.03 2.26 
 
 
Table 4. 12 Concentration and Purity of DNA after clean-up of 1.2kb fragment 
Sample ID ng/µl A260/280nm 
MH1 73.64 2.05 
BH2 134.77 1.95 
MH3 24.4 2.05 
BH3 137.59 2.01 
MH4 32.87 1.86 
 
 
None of the amplified PCR products for the 2.5kb fragment were diluted since the DNA 
concentration required for the sequencing reaction was within the recommended range (20-
50ng/µl). However, for the 1.2 kb fragment, samples MH1, BH2 and BH3 were diluted with 
buffer EB from the QIAquick purification kit so their DNA concentrations were within the 
recommended range (10-40ng/µl). 
 
The sequences were analysed, the ends were trimmed and the different sections amplified by the 
14 primers were aligned to obtain a contiguous sequence. The contiguous sequence was then 
aligned with whole genome sequences from GenBank and trimmed to obtain the 3.2kb sequence 
in the five patients. 
 
The five sequences were used to construct a phylogenetic tree (figure 4.5). The HBV strains 
from the mother-child pair MH3/BH3 were identical. 
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Figure 4. 6 Phylogenetic tree of five patients with HBV strains belonging to subgenotype A1 
based on whole genome sequences. Sequences with accession numbers AY233277.1, 
AY233279.1, AY233286.1, AY233287.1, AY903452.1, AY233290.1 and GQ184326.1 were 
downloaded from GenBank. All sequences belong to subgenotype A1 except for GQ184326.1 
which belongs to genotype C. 
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei 1987). 
The optimal tree with the sum of branch length = 0.21123244 is shown. The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. The evolutionary distances were computed using the Kimura 2-parameter 
method (Kimura 1980) and are in the units of the number of base substitutions per site. The 
analysis involved 12 nucleotide sequences. There were a total of 3209 positions in the final 
dataset. Evolutionary analyses were conducted in MEGA5 (Tamura et al. 2011).   
 AY233279.1 SA A
 AY233287.1 SA A
 AY233277.1 SA A
 AY233290.1 SA A
 BH3
 MH3
 AY903452.1 SA A1
 MH1
 BH2
 MH4
 AY233286.1 SA A
 GQ184326.1 SA C1
0.01
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CHAPTER FIVE: DISCUSSION 
 
This study has shown the prevalence of HBsAg and HBV infection in a cohort of HIV-exposed 
infants to be 0.3% (3/1000) and 0.4% (4/1000) respectively. Two of the three HBsAg positive 
infants were HBeAg positive. On follow-up three months later, two of three HBV-infected 
infants remained positive for HBsAg and HBV DNA. These two infants were both male and 
HIV-uninfected. All four mothers who transmitted HBV to their infants were HBeAg positive 
and not on ART. The two mother infant pairs had identical sequences. This is the first study 
showing vertical transmission of HBV in HIV-exposed infants in South Africa in the context of 
HBV vaccination. 
 
Prevalence of HBsAg 
 
In comparison to a study by Simani et al. (2009), the rate of HBsAg positivity observed in this 
study is lower. They found an HBsAg carriage of 0.9% (3/303) in vaccinated children between 
the ages of 5 and 24 months, two of whom were HIV-infected. However, the Simani study 
looked at a much smaller cohort attending one clinic and one hospital serving mainly a peri-
urban and urban population in Gauteng of whom 36% were HIV-infected. In contrast, in the 
current study, a larger cohort of 1000 HIV-exposed infants was tested of whom only 6% were 
HIV-infected. This is a more accurate representation of the prevalence in the community given 
that the number of HIV-exposed uninfected (HEU) infants in South Africa far exceeds the 
number of HIV-infected infants. 
 
In the context of the HIV epidemic, it is expected that the prevalence of infection found in this 
study should be higher. However, it was observed that none of the mothers who transmitted the 
virus to their infants in the current study were on ART and all had CD4 counts greater than 350 
cells/mm
3
. It is therefore possible that a proportion of mothers of the tested infants in this cohort 
would have been on ART during pregnancy and therefore exposed to tenofovir/lamivudine. 
These drugs would have reduced the maternal HBV DNA levels thus inadvertently protecting the 
HIV-exposed infants in this cohort from perinatal infection with HBV and would explain the low 
prevalence of vertical transmission of HBV in HIV-exposed infants. 
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This study has clearly demonstrated that HEU infants are at risk of infection with HBV. Two 
South African studies carried out in 1995-1999 by Tsebe et al. (2001) and in 1996-1997 by Hino 
et al. (2001) found no transmission of HBV in 598 and 1213 vaccinated children respectively. 
The cohort in both studies consisted of older children (8-72 months for the Tsebe study and 12-
24 months for the Hino study) of unspecified HIV status. In the Tsebe study, these children were 
recruited from various primary health care clinics and hospitals from the Northern Province and 
the Hino study tested children from the Eastern Cape. The current study tested children between 
the ages of 0 and 18 months but the median age of the cohort was 1.5 months making this study 
reliable for looking at vertical transmission of HBV. Furthermore, the tested samples came from 
various clinics, making this the first community-based study looking at the prevalence of HBV in 
HIV-exposed infants in the Western Cape.  
 
Extrapolating from the paediatric HBsAg prevalence before the introduction of HBV vaccination 
(Abdool Karim et al. 1988; Prozesky et al. 1983; Vardas et al. 1999), it is clear that this 
intervention has been successful in decreasing the prevalence of HBsAg in the paediatric 
population. However, this study has shown that transmission of HBV is occurring from HIV-
infected women who are not on combination antiretroviral therapy, to their infants. The data also 
shows that this transmission is vertical and not horizontal as was postulated in the pre-HIV era 
(Whittle et al. 1983). 
 
Vertical transmission 
 
Maternal plasma samples were unavailable at the screening stage and it was therefore not 
possible to determine the rate of HBsAg and HBeAg positivity in the mothers of the infants who 
were HBsAg negative. However, an antenatal community-based seroprevalence study of 1543 
HIV-infected and 1546 HIV-uninfected pregnant women from the Western Cape carried out in 
2012 (Maponga TG, MSc Thesis, Stellenbosch University, 2012) showed the prevalence of 
HBsAg and HBeAg in HIV-infected mothers to be 3.4% (95% CI: 2.5%, 4.3%) and 18% 
respectively. 
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Another study conducted in the Northern Province by Tsebe et al. (2001) showed that the 
prevalence of HBsAg in mothers of vaccinated children was 3.2%, although the HIV status of 
these mothers was not reported and only one mother was found to be HBeAg-positive.  
 
The prevalence of HBsAg observed in the community based study of HIV-infected women from 
the Western Cape (Maponga TG, MSc Thesis, Stellenbosch University, 2012) was considered to 
reflect the maternal HBV prevalence of this cohort. This figure was used to calculate the rate of 
vertical transmission. Using the prevalence of HBV infection of 0.4% in this cohort of HIV-
exposed infants and HBsAg positivity of 3.4% (53/1543, 95% CI 2.5% to 4.3%) in HIV-infected 
women, the rate of MTCT of HBV was calculated to be 12% (Figure 5.1).  
 
 
 
Figure 5. 1 Calculations for rate of transmission of HBV in HIV-exposed infants 
 
In comparison, in neighbouring Namibia, a study conducted by Botha et al. (1984) showed the 
prevalence of HBsAg in a group of mothers to be 11% but their HBeAg status was unknown. 
Cord blood testing showed that 27% of the unvaccinated newborns of the HBsAg positive 
mothers were positive for HBsAg. However, contamination of cord blood with maternal blood 
was a possibility and these infants were not retested to verify their status (Botha et al. 1984). No 
post-vaccine studies looking specifically at the rates of MTCT of HBV have been previously 
conducted in South Africa. 
 
The Tsebe study also showed that one out of four tested HBsAg positive mothers was positive 
for HBeAg and the remaining three mothers were antiHBe positive/HBeAg negative. None of 
the mothers transmitted the virus to their children. In comparison, the mothers of the four 
infected infants identified in this study were all HBeAg positive and at follow-up, three still had 
a high viral load which is a risk factor for MTCT of HBV (Burk et al. 1994). All four mothers 
had CD4 counts above 350 cells/mm
3
 and were therefore not on ART. First line ART for 
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pregnant women with CD4 counts below 350 cells/mm
3
 includes tenofovir and lamivudine 
(National Department of Health, South Africa and South African National AIDS Council 2010). 
The use of these drugs will decrease HBV viral load (Pan et al. 2012; Shi et al. 2010; van 
Zonneveld et al. 2003; Xu et al. 2009). This is the likely explanation for why transmission only 
occurred in mothers who were not on ART. 
 
Sequencing analysis and significance 
 
The HBV strains sequenced from the two infants and the four mothers belong to subgenotype 
A1. This is known to be the most prevalent circulating strain of HBV in South Africa (Kramvis 
and Kew 2007). HBV strains circulating in South Africa have been previously characterised 
(Bowyer et al. 1997; Kimbi et al. 2004; Kramvis et al. 2002; Owiredu et al. 2001a, Owiredu et al. 
2001b) but very few have been sequenced from patients residing in the Western Cape. This data 
will therefore contribute to the existing data on circulating strains in the Western Cape. 
  
Phylogenetic analysis based on the surface gene showed that the two mother-child pairs were 
infected with identical strains of HBV giving further proof that the infection was of maternal 
origin given the young age of these infants. This is the first study looking at HBV sequences 
obtained from mother and child pairs in South Africa. 
 
No drug-resistance mutations were observed in this cohort. This is not surprising given that the 
mothers were not on ART, although mutations have previously been observed in the YMDD 
motif (where mutations leading to lamivudine resistance commonly occur) in treatment-naïve 
patients (Selabe et al. 2007). The roll-out of tenofovir as part of first-line ART will further 
reduce the risk of these mutations emerging. 
 
All the six HBV strains characterised in this study clustered with South African strains belonging 
to subgenotype A1, but they were genetically closer to the Western Cape sequences compared to 
the sequences from other provinces. 
Infection with HBV strains of genotype A has a higher likelihood of leading to chronicity 
compared to other genotypes (Lin and Kao 2011). A South African study also showed that 
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infection with subgenotype A1 had a 4.5-fold risk of HCC development compared to infection 
with non-A genotypes (Kew et al. 2005). In subSaharan Africa, chronic carriers of HBV progress 
to HCC early, with the highest rates of cancer developing at around 45 years (Yang and Roberts 
2010). Male patients have been shown to be two to seven times more likely to develop HCC than 
women (Yang and Roberts 2010). 
 
The two infants who were found to still be infected on follow-up are highly likely to become 
chronic carriers and are therefore at high risk of developing HCC during the most productive 
years of their lives. Perinatally-infected chronic carriers normally experience an immunotolerant 
phase where they are highly infectious but show no symptoms of infection. They can therefore 
transmit the virus, not only to their playmates who may not have been vaccinated, but also to 
their care-givers. The ways in which the virus is transmitted horizontally are not clearly 
understood (Alter 2003) but contact of broken skin or mucous membranes with even small 
amounts of blood and other bodily fluids from an infected person (Alter 2003) are the most likely 
modes of transmission. In addition, the virus can survive on surfaces for at least seven days 
(Bond et al. 1981) and has been found on various household objects touched frequently by 
chronically infected infants (Petersen et al. 1976). Transmission of HBV through bites has also 
been demonstrated (Stornello et al. 1991, Hui et al. 2005). Therefore, unvaccinated children and 
adults who are in close contact with the persistently-infected infants from this study are at high 
risk of being infected with HBV. 
 
Prevalence of HBeAg/AntiHBe 
 
Two out of three followed-up infected infants in this study were HBeAg-positive. In contrast, 
Botha et al. (1984) showed that in unvaccinated Namibian infants younger than one year, the 
prevalence of HBsAg was 2.7% and 29% of the HBsAg positives were positive for HBeAg. 
However, only 1% of the infected infants in that age group was younger than six months. A 
study by Abdool Karim et al. in 1988 showed that in a cohort of 136 urban unvaccinated children 
less than two years old, only two of the tested children were positive for HBsAg and one out of 
the two children was positive for HBeAg. However, compared to the current study, none of the 
Stellenbosch University http://scholar.sun.ac.za
 102 
 
HBsAg positive urban infants were under one year of age. The same study found that 25% of 
institutionalized infants younger than two years were HBsAg positive and 40% of the HBsAg 
positives were positive for HBeAg. However, only 20 participants were enrolled in that 
particular age group and the rates of infection observed would not reflect the prevalence in the 
general population.  
 
Although the prevalence of HBeAg in the HBsAg positive infants in the current study was higher 
than seen in the Botha and Abdool Karim studies, the number of infected infants was too low to 
draw any definite conclusions and more studies are needed to evaluate the differences in HBeAg-
positivity between HIV-exposed and HIV-unexposed infants. 
 
HBV DNA levels 
 
A viral load of >10
8
 IU/ml was observed in two out of three tested HBV infected infants at 
follow-up in the current study. Simani et al. (2009) reported ‘a low level viraemia’ in 1.3% of 
their cohort of 303 HIV-infected and uninfected infants although they did not use a quantitative 
assay for DNA testing. A study by Hino et al. (2001) reported a prevalence of HBsAg of 7.8% in 
an unvaccinated cohort of children and showed a decrease from 6.5% to 0.3% in HBV DNA 
detection in vaccinated children compared to unvaccinated children from the Eastern Cape. 
Tsebe et al. (2001) did not detect HBV DNA in their cohort of vaccinated children. The HIV 
status of the children tested in the Tsebe and Hino studies was not stated. 
 
This is therefore the first report persistently high hepatitis B viral loads in vaccinated South 
African HIV-exposed infants. 
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Significance of the study 
 
Four infants were found to be infected with HBV in this study. These infants were first tested in 
the first three months of life, where they are mostly in contact with their mothers who were 
HBeAg-positive and would have minimal interactions with other individuals. These infants were 
therefore considered to be vertically infected. The first blood sample was taken from these 
infants either on the same day or very close to the first day they were vaccinated against HBV 
eliminating the possibility that the infections observed were breakthrough infections. In addition, 
phylogenetic analysis showed two mother-child paired sequences were identical confirming that 
the transmission was maternal in origin. 
 
This transmission occurred despite complete and timely vaccination of the infected infants at six 
weeks, ten weeks and fourteen weeks. Two of the three followed up infected infants were still 
positive for HBV infection three months later. It is therefore clear that the current immunization 
schedule has failed in its role to protect these infants from HBV infection. 
 
This schedule was based on studies showing that transmission of HBV occurred horizontally 
mainly in childhood and that vertical transmission was minimal. However, in the context of the 
HIV epidemic, where HIV-infected mothers show less HBeAg seroconversion (Thio 2009), the 
risk of vertical transmission is much higher. However, administering a birth dose of the HB 
vaccine will reduce the risk of transmission of HBV from HBeAg-positive mothers to their 
infants by approximately 75% (Beasley et al. 1983). 
 
HBV vaccination at birth alone however will not prevent all vertical infections. Mothers with 
high viral loads (>10
5
 IU/ml) are at high risk of infecting their infants (Burk et al. 1994) despite 
the administration of the HB vaccine to the neonates at birth (Lee et al. 1986). In the current 
study, three of the four mothers who transmitted HBV to their infants had a viral load of greater 
than 10
7
 IU/ml. The fourth mother had a lower viral load of 10
3
 IU/ml but since she showed 
HBeAg seroconversion at follow-up, it is likely that her viral load was much higher at the time of 
delivery.  
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Treating women with high viral loads with nucleos(t)ides will reduce the risk of transmission. 
When done in conjunction with the administration of a birth dose of the HB vaccine, the risks of 
MTCT are further reduced. Clinical trials have shown the efficacy of lamivudine in reducing the 
risks of MTCT in HBV-infected women and did not report any serious side effects (van 
Zonneveld et al. 2003; Xu et al. 2009). However, the use of lamivudine in co-infected patients is 
not recommended because of its low genetic barrier. A retrospective study has shown that the use 
of tenofovir significantly reduced the viral loads in HBV-infected mothers and none of their 
infants were positive for HBsAg at 28-36 weeks after delivery (Pan et al. 2012). However, in 
these studies, HBIg and the birth dose of the vaccine were administered to the neonates and it is 
therefore not known what the efficacy would be in the absence of the use of HBIg. Nonetheless, 
knowing that the use of the birth dose of the vaccine will reduce transmission by 75% (Beasley 
et al. 1983), it is expected that the concomitant administration of the vaccine at birth and the use 
of nucleos(t)ide analogues will decrease MTCT of HBV considerably. 
 
Since this study only recruited HIV-exposed babies, the rate of transmission observed in this 
study cannot be extrapolated to the HIV-unexposed paediatric population. The antenatal study 
from the Western Cape showed the prevalence of HBeAg in HIV-uninfected women to be 15% 
(Maponga TG, MSc Thesis, Stellenbosch University, 2012). Given this HBeAg prevalence, and 
knowing that none of the HIV-infected women would be on antiHBV therapy, it is highly likely 
that vertical transmission of HBV is occurring in that group. Further studies are required to 
investigate the prevalence of HBV in HIV-uninfected infants. 
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Proposals to address the problem of HBV MTCT 
 
This study has shown that vertical transmission of HBV is occurring in South Africa and that the 
current immunization schedule does not protect infants from vertical transmission of HBV. It is 
therefore proposed that the HB vaccine be administered at birth. The HB vaccine is safe and can 
be administered at birth with no serious adverse effects reported except for transient fever and 
pain at the site of injection (Romano et al. 2011).  
 
Most HIV-exposed infants born in South Africa are uninfected at birth but still show immune 
impairments which are associated with their exposure to the HIV virus making them more prone 
to infections with more severe outcomes (Filteau 2009). However, Jones et al. (2011) showed 
that although HEU infants receive lower levels of protective antibodies from their mothers they 
mount robust responses to vaccination. As all the HBV-infected infants in this cohort were HIV-
uninfected, it is likely therefore that administration of the vaccine at birth will benefit those 
infants. 
 
Currently, a single-antigen HB vaccine is given to infants at six weeks. For women who deliver 
in clinics and hospitals, the same vaccine can be administered concomitantly with the BCG 
vaccine, another vaccine which should be given at or near delivery. It has been pointed out that 
there are some logistical problems associated with coverage and timeliness of a birth dose of the 
vaccine in the South African context (Kramvis and Clements 2010). An unknown proportion of 
women, still give birth at home in South Africa and their infants would therefore not have access 
to the vaccine within 24 hours of delivery as recommended by the WHO (Kramvis and Clements 
2010). A community outreach approach as described in an Indonesian study (Ruff et al. 1995) 
could be used to target those infants and the single-antigen vaccine could be administered within 
seven days of birth by health workers from the nearest clinics catering to the mothers who 
deliver at home (Marion et al. 1994; Ruff et al. 1995). A study in Indonesia, a country with a rate 
of vertical transmission of HBV of 25% (Ruff et al. 1995), showed that administering the HB 
vaccine within seven days of delivery decreased the prevalence of HBsAg from 6.2% to 1.4% in 
infants (Ruff et al. 1995). 
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For long-term purposes, the use of Uniject™, a single-dose, auto-disable injection device, 
prefilled with hepatitis B vaccine (HB-Uniject) could be considered for use on the infants who 
are born at home. The use of HB-Uniject was shown to be cost-effective and to increase 
coverage of the birth dose of the HB vaccine among infants who are born at home in another 
Indonesian study (Levin et al. 2005). However, 79% of women deliver at home in Indonesia 
(Levin et al. 2005) and this may not reflect the situation in Africa. To determine the practicality 
of this approach in the African setting, studies are needed to find out what proportion of women 
give birth at home and whether the use of the HB-Uniject would be cost-effective. 
 
Secondly, in order to identify those mothers with high viral loads, at risk of transmitting 
infection to their infants, pregnant women should be screened at booking for HBsAg and if 
positive, they should be further tested for HBeAg. Once identified, these women should be 
treated with a nucleos(t)ide analogue to reduce their HBV viral loads (Dusheiko 2012; Shi et al. 
2010; Tran 2012) and therefore decrease the risks of MTCT. 
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LIMITATIONS 
 
The results of this study should be interpreted in the context of the limitations in the study 
design. 
 
It is likely that ART reduced the rate of HBV transmission in this cohort, but since we did not 
know what proportion of mothers who were HBsAg positive were on ART, nor what the viral 
loads were at delivery we were not able to quantify this. 
 
Furthermore, the HBV DNA levels at the time of delivery of the mothers who transmitted HBV 
to their infants are not known and could only be estimated based on the viral loads observed at 
follow-up. However, given that they were not on ART during pregnancy, it is highly likely that 
the viral loads at delivery were similar to the ones at follow-up. 
 
This study only looked at the infants of mothers who have regular follow-ups at their local 
clinics. Infants whose mothers do not come for regular follow-ups were therefore missed in this 
cohort. These could have included mothers who were too sick to come to the clinics. 
 
Lastly, only samples which had a minimum of 100µl of plasma were selected for testing and 
therefore, there is a risk of sampling bias in the collection procedure as possibly samples from a 
certain clinic could have been favoured over others. However, this is negated by the fact the 
number of samples collected from all the clinics were proportional to the number of samples 
received from those same clinics by the NHLS. 
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CHAPTER SIX: CONCLUSION 
  
This study has described a HBV prevalence of 0.4% (4/1000) in a large HIV-exposed paediatric 
population. This study has also reported persistence of HBV infection and elevated viral loads at 
follow up in two of the four infected infants. It has been shown that the likely route of infection 
in these two infants was vertical transmission. 
 
The mothers of the four infected children were not on ART, all were positive for HBeAg and 
three of four mothers had viral loads of >10
8
 IU/ml. These three mothers would be at risk of 
transmitting HBV to their infants (Burk et al. 1994), even if HB vaccine had been administered 
at the time of birth (Lee et al. 1986). These mothers should be identified by screening for HBsAg 
and then HBeAg, and where possible HBV viral load. The institution of nucleos(t)ide therapy 
early in the third trimester will reduce the risk of HBV transmission, together with a change in 
the timing of HBV vaccination to around the time of birth.  
 
The prevalence of HBV transmission in HIV-uninfected women is not known, but it is proposed 
that in the absence of antiviral therapy and a prevalence of HBeAg positivity of 15% in HIV-
uninfected women in the Western Cape (Maponga TG, MSc Thesis, Stellenbosch University, 
2012), the risk of transmission may be even higher in HIV-uninfected women than that described 
here. This too supports the introduction of antenatal screening for HBsAg with the view to 
administer tenofovir to those at high risk of HBV transmission and early vaccination of the 
infant. 
 
This study has described an important problem in current HBV public health policy and has 
shown that there is a serious need to re-examine the current immunization schedule in South 
Africa and to change the timing of HBV vaccination to include a birth dose of the vaccine. 
 
Further studies are needed to determine the risk of HBV transmission in HIV-unexposed infants, 
to perform a cost-benefit analysis of screening women for HBsAg in pregnancy and to determine 
the operational problems associated with screening and the introduction of a birth dose of HBV 
vaccination.  
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